DE19742275A1 - Use of branched-chain alkyl alkanoate esters - Google Patents
Use of branched-chain alkyl alkanoate estersInfo
- Publication number
- DE19742275A1 DE19742275A1 DE1997142275 DE19742275A DE19742275A1 DE 19742275 A1 DE19742275 A1 DE 19742275A1 DE 1997142275 DE1997142275 DE 1997142275 DE 19742275 A DE19742275 A DE 19742275A DE 19742275 A1 DE19742275 A1 DE 19742275A1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- cosmetic
- skin
- substances
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000002148 esters Chemical class 0.000 title claims abstract description 31
- 125000000217 alkyl group Chemical group 0.000 title abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 6
- 230000001857 anti-mycotic effect Effects 0.000 claims abstract description 5
- 230000002141 anti-parasite Effects 0.000 claims abstract description 4
- 239000003096 antiparasitic agent Substances 0.000 claims abstract description 4
- 239000003429 antifungal agent Substances 0.000 claims abstract description 3
- 239000003443 antiviral agent Substances 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 description 47
- 238000002360 preparation method Methods 0.000 description 36
- 239000000126 substance Substances 0.000 description 32
- 239000002304 perfume Substances 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 31
- 239000003755 preservative agent Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- -1 alkyl radicals Chemical class 0.000 description 22
- 210000004209 hair Anatomy 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 239000002781 deodorant agent Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 241000700605 Viruses Species 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 241000640882 Condea Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 206010042566 Superinfection Diseases 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 241000894007 species Species 0.000 description 9
- WAYINTBTZWQNSN-UHFFFAOYSA-N 11-methyldodecyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CC(C)CC(C)(C)C WAYINTBTZWQNSN-UHFFFAOYSA-N 0.000 description 8
- PIODUORJBYXSQY-UHFFFAOYSA-N 2-ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O.CCCCC(CC)C(O)=O PIODUORJBYXSQY-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 244000045947 parasite Species 0.000 description 8
- 208000001840 Dandruff Diseases 0.000 description 7
- 239000005662 Paraffin oil Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000002453 shampoo Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 208000031888 Mycoses Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- 208000007163 Dermatomycoses Diseases 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 206010061217 Infestation Diseases 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000000282 nail Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 230000036642 wellbeing Effects 0.000 description 5
- 208000035985 Body Odor Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 206010039792 Seborrhoea Diseases 0.000 description 4
- 206010040904 Skin odour abnormal Diseases 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 244000005706 microflora Species 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 230000003071 parasitic effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 244000005714 skin microbiome Species 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000004243 sweat Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- ZPGSXEKHMWBPPO-UHFFFAOYSA-N 2-butyloctyl 2-butyloctanoate Chemical compound CCCCCCC(CCCC)COC(=O)C(CCCC)CCCCCC ZPGSXEKHMWBPPO-UHFFFAOYSA-N 0.000 description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 3
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- BJMMJWWRCOVZJM-UHFFFAOYSA-N 2-butyloctyl 2-butyldecanoate Chemical compound CCCCCCCCC(CCCC)C(=O)OCC(CCCC)CCCCCC BJMMJWWRCOVZJM-UHFFFAOYSA-N 0.000 description 2
- HQEKCIFEAWMJHK-UHFFFAOYSA-N 2-butyloctyl 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OCC(CCCC)CCCCCC HQEKCIFEAWMJHK-UHFFFAOYSA-N 0.000 description 2
- BRORPGSJXSLXKN-UHFFFAOYSA-N 6-methylheptyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCOC(=O)CC(C)CC(C)(C)C BRORPGSJXSLXKN-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000223782 Ciliophora Species 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000221785 Erysiphales Species 0.000 description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 241000555688 Malassezia furfur Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000238887 Ornithodoros Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 241000509416 Sarcoptes Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 150000008366 benzophenones Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000002468 fat body Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940100608 glycol distearate Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001023 inorganic pigment Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical group COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- KXTAOXNYQGASTA-UHFFFAOYSA-N 2-benzylidenepropanedioic acid Chemical compound OC(=O)C(C(O)=O)=CC1=CC=CC=C1 KXTAOXNYQGASTA-UHFFFAOYSA-N 0.000 description 1
- RGCASHYLRJJOOW-UHFFFAOYSA-N 2-butyloctyl 2-octyldodecanoate Chemical compound CCCCCCCCCCC(CCCCCCCC)C(=O)OCC(CCCC)CCCCCC RGCASHYLRJJOOW-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- GWXXFGWOWOJEEX-UHFFFAOYSA-N 4,4,4-trihydroxy-1-phenylbutan-1-one Chemical compound OC(CCC(=O)C1=CC=CC=C1)(O)O GWXXFGWOWOJEEX-UHFFFAOYSA-N 0.000 description 1
- 125000002528 4-isopropyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XZOYHFBNQHPJRQ-UHFFFAOYSA-N 7-methyloctanoic acid Chemical compound CC(C)CCCCCC(O)=O XZOYHFBNQHPJRQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000238679 Amblyomma Species 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 241001480748 Argas Species 0.000 description 1
- 241001480752 Argas persicus Species 0.000 description 1
- 241000244185 Ascaris lumbricoides Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 241001235572 Balantioides coli Species 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000191796 Calyptosphaeria tropica Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241000191839 Chrysomya Species 0.000 description 1
- 241001124179 Chrysops Species 0.000 description 1
- 241001635683 Cimex hemipterus Species 0.000 description 1
- 241001327638 Cimex lectularius Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000304166 Cordylobia Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000490513 Ctenocephalides canis Species 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 206010011668 Cutaneous leishmaniasis Diseases 0.000 description 1
- 241000205707 Cystoisospora belli Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 241000193880 Demodex folliculorum Species 0.000 description 1
- 241001480824 Dermacentor Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000202813 Dermatobia Species 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 208000006004 Flea Infestations Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 241000250507 Gigaspora candida Species 0.000 description 1
- 241000257324 Glossina <genus> Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001480796 Haemaphysalis Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000224421 Heterolobosea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 241000221775 Hypocreales Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- GMIPYROQJHDYBM-NSCUHMNNSA-N Isotridecenoic acid Chemical compound C\C=C\CCCCCCCCCC(O)=O GMIPYROQJHDYBM-NSCUHMNNSA-N 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241000954436 Leandra diffusa Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000067829 Lilaeopsis brasiliensis Species 0.000 description 1
- 241000257162 Lucilia <blowfly> Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 241001375804 Mastigophora Species 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 241000224438 Naegleria fowleri Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 244000020186 Nymphaea lutea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000919533 Panstrongylus megistus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000233679 Peronosporaceae Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000722350 Phlebotomus <genus> Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241001208007 Procas Species 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241001675082 Pulex Species 0.000 description 1
- 241000238706 Pyemotes Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 241000842539 Rhagades Species 0.000 description 1
- 241000722249 Rhodnius prolixus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- ARCJQKUWGAZPFX-KBPBESRZSA-N S-trans-stilbene oxide Chemical compound C1([C@H]2[C@@H](O2)C=2C=CC=CC=2)=CC=CC=C1 ARCJQKUWGAZPFX-KBPBESRZSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241001494139 Stomoxys Species 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 241000255626 Tabanus <genus> Species 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010053188 Torulopsis infection Diseases 0.000 description 1
- 241001414833 Triatoma Species 0.000 description 1
- 241000919558 Triatoma brasiliensis Species 0.000 description 1
- 241001414831 Triatoma infestans Species 0.000 description 1
- 241000919565 Triatoma sordida Species 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241001489145 Trichuris trichiura Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241001584775 Tunga penetrans Species 0.000 description 1
- 241000611866 Tyrophagus putrescentiae Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000353224 Xenopsylla Species 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- NNCOOIBIVIODKO-UHFFFAOYSA-N aluminum;hypochlorous acid Chemical compound [Al].ClO NNCOOIBIVIODKO-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003001 amoeba Anatomy 0.000 description 1
- 230000005167 amoeboid movement Effects 0.000 description 1
- 230000001998 anti-microbiological effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 208000007456 balantidiasis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- DTVQVQGCVNNOSX-UHFFFAOYSA-N bis(2-ethylhexyl) 2-[(4-methoxyphenyl)methylidene]propanedioate Chemical compound CCCCC(CC)COC(=O)C(C(=O)OCC(CC)CCCC)=CC1=CC=C(OC)C=C1 DTVQVQGCVNNOSX-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229940079886 disodium lauryl sulfosuccinate Drugs 0.000 description 1
- JMGZBMRVDHKMKB-UHFFFAOYSA-L disodium;2-sulfobutanedioate Chemical compound [Na+].[Na+].OS(=O)(=O)C(C([O-])=O)CC([O-])=O JMGZBMRVDHKMKB-UHFFFAOYSA-L 0.000 description 1
- KHIQYZGEUSTKSB-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O.CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O KHIQYZGEUSTKSB-UHFFFAOYSA-L 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QVBODZPPYSSMEL-UHFFFAOYSA-N dodecyl sulfate;2-hydroxyethylazanium Chemical compound NCCO.CCCCCCCCCCCCOS(O)(=O)=O QVBODZPPYSSMEL-UHFFFAOYSA-N 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- MJVGBKJNTFCUJM-UHFFFAOYSA-N mexenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(C)C=C1 MJVGBKJNTFCUJM-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940069822 monoethanolamine lauryl sulfate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N nordihydroguaiaretic acid Chemical compound C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- LXTZRIBXKVRLOA-UHFFFAOYSA-N padimate a Chemical compound CCCCCOC(=O)C1=CC=C(N(C)C)C=C1 LXTZRIBXKVRLOA-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 206010033794 paragonimiasis Diseases 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 208000005814 piedra Diseases 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000003779 seborrheic infantile dermatitis Diseases 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- ARCJQKUWGAZPFX-UHFFFAOYSA-N stilbene oxide Chemical compound O1C(C=2C=CC=CC=2)C1C1=CC=CC=C1 ARCJQKUWGAZPFX-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical class OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 201000001064 tick infestation Diseases 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical class OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012873 virucide Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/24—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
- A61Q1/06—Lipsticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q9/00—Preparations for removing hair or for aiding hair removal
- A61Q9/02—Shaving preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft die Verwendung an sich bekannter Substanzen als gegen Bakterien, Mycota und Viren wirksame Substanzen. In besonderen Ausfüh rungsformen betrifft die vorliegende Erfindung kosmetische und dermatologische Zubereitungen, solche Substanzen enthaltend.The present invention relates to the use of substances known per se as substances effective against bacteria, mycota and viruses. In a special version The present invention relates to cosmetic and dermatological forms Preparations containing such substances.
Der gesunde warmblütige Organismus, insbesondere die gesunde menschliche Haut, ist mit einer Vielzahl nichtpathogener Mikroorganismen besiedelt. Diese sogenannte Mikroflora der Haut ist nicht nur unschädlich, sie stellt einen wichtigen Schutz zur Abwehr opportunistischer oder pathogener Keime dar.The healthy warm-blooded organism, especially the healthy human skin, is populated with a large number of non-pathogenic microorganisms. This so-called Microflora of the skin is not only harmless, it provides important protection Defense against opportunistic or pathogenic germs.
Bakterien gehören zu den prokaryotischen Einzellern. Sie können grob nach ihrer Form (Kugel, Zylinder, gekrümmter Zylinder) sowie nach dem Aufbau ihrer Zellwand (grampositiv, gramnegativ) unterschieden werden. Feinere Unterteilungen tragen auch der Physiologie der Organismen Rechnung. So existieren aerobe, anaerobe so wie fakultativ anaerobe Bakterien. Manche Individuen sind in ihrer Eigenschaft als pa thogene Keime von medizinischer Bedeutung, andere wiederum sind vollkommen harmlos.Bacteria are prokaryotic unicellular organisms. You can roughly follow theirs Shape (ball, cylinder, curved cylinder) as well as after the construction of their cell wall (gram positive, gram negative). Wear finer subdivisions also take into account the physiology of organisms. So aerobic, anaerobic exist like facultative anaerobic bacteria. Some individuals are in their capacity as pa thogenic germs of medical importance, others are perfect harmless.
Gegen Bakterien wirksame Substanzen sind seit geraumer Zeit bekannt. Der Begriff "Antibiotika" beispielsweise, der nicht auf alle antimikrobiell wirksamen Substanzen anwendbar ist, läßt sich auf das Jahr 1941 datieren, obwohl die ersten Erkenntnisse zum Penicillin bereits im Jahre 1929 gefunden wurden. Antibiotika im heutigen Sinne sind nicht für alle medizinischen, schon gar nicht kosmetische Anwendungen geeig net, da häufig auch der warmblütige Organismus, also etwa der erkrankte Patient, bei Anwendung auf irgendeine Weise in seinen Stoffwechselfunktionen beeinträchtigt wird.Substances effective against bacteria have been known for some time. The term "Antibiotics" for example, which does not act on all antimicrobial substances applicable, can be dated to 1941, although the first findings for penicillin were found as early as 1929. Antibiotics in today's sense are not suitable for all medical and certainly not cosmetic applications net, since often the warm-blooded organism, e.g. the sick patient, also Use in any way impaired in its metabolic functions becomes.
Eine Aufgabe der vorliegenden Erfindung war also, den Stand der Technik in dieser Richtung zu bereichern, insbesondere also, Substanzen zur Verfügung zu stellen, welche gegen grampositive und/oder gramnegative Bakterien wirksam sind, ohne daß mit der Anwendung der Substanzen eine unvertretbare Beeinträchtigung der Ge sundheit des Anwenders verbunden wäre.An object of the present invention was therefore the state of the art in this To enrich direction, in particular to make substances available, which are effective against gram-positive and / or gram-negative bacteria, without that with the application of the substances an unacceptable impairment of the Ge health of the user would be connected.
Gramnegative Keime sind beispielsweise Escherichia coli, Pseudomonas-Arten sowie Enterobacteriaceen, wie etwa Citrobacter.Gram-negative germs are, for example, Escherichia coli, Pseudomonas species and Enterobacteriaceen, such as Citrobacter.
Auch grampositive Keime spielen in Kosmetik und Dermatologie eine Rolle. Bei der unreinen Haut beispielsweise sind neben anderen Einflüssen bakterielle Sekundärin fektionen von ätiologischer Bedeutung. Einer der wichtigsten Mikroorganismen, der in Zusammenhang mit unreiner Haut steht, ist Propionibacterium acnes.Gram-positive germs also play a role in cosmetics and dermatology. In the Impure skin, for example, is a bacterial secondary, among other influences infections of etiological importance. One of the most important microorganisms in Related to blemished skin is Propionibacterium acnes.
Unreine Haut und/oder Komedonen beeinträchtigen das Wohlbefinden der Betroffe nen aber selbst in leichten Fällen. Da praktisch jeder oder jede Jugendliche von un reiner Haut irgendeiner Ausprägung betroffen ist, besteht bei vielen Personen Bedarf, diesem Zustande abzuhelfen.Impure skin and / or comedones affect the well-being of those affected but even in mild cases. Since practically every or every young person from un pure skin of any kind is affected, there is a need for many people, to remedy this condition.
Eine besondere Aufgabe der vorliegenden Erfindung war es also, einen gegen unrei ne Haut bzw. Propionibacterium acnes wirksamen Stoff bzw. Stoffkombination zu fin den.A particular object of the present invention was therefore to provide one against immature ne skin or Propionibacterium acnes active substance or combination of substances to fin the.
Die vorliegende Erfindung betrifft in einer weiteren Ausführungsform kosmetische Des odorantien. Solche Formulierungen dienen dazu, Körpergeruch zu beseitigen, der ent steht, wenn der an sich geruchlose frische Schweiß durch insbesondere grampositive Mikroorganismen zersetzt wird. Den üblichen kosmetischen Desodorantien liegen unter schiedliche Wirkprinzipien zugrunde.In a further embodiment, the present invention relates to cosmetic des odorants. Such formulations serve to eliminate body odor, which ent stands when the odorless fresh sweat in particular through gram-positive Microorganisms is decomposed. The usual cosmetic deodorants are below different principles of action.
Bekannt und gebräuchlich sind sowohl flüssige Desodorantien, beispielsweise Aerosol sprays, Roll-ons und dergleichen als auch feste Zubereitungen, beispielsweise Deo-Stif te ("Sticks"), Puder, Pudersprays, Intimreinigungsmittel usw.Both liquid deodorants, for example aerosol, are known and customary sprays, roll-ons and the like as well as solid preparations, for example deodorant sticks te ("sticks"), powder, powder sprays, intimate cleansers, etc.
In sogenannten Antitranspirantien kann durch Adstringentien - vorwiegend Aluminium salze wie Aluminiumhydroxychlorid (Aluchlorhydrat) - die Entstehung des Schweißes un terbunden werden. Abgesehen von der Denaturierung der Hautproteine greifen die da für verwendeten Stoffe aber, abhängig von ihrer Dosierung, drastisch in den Wärme haushalt der Achselregion ein und sollten allenfalls in Ausnahmefällen angewandt wer den.In so-called antiperspirants, astringents - mainly aluminum salts such as aluminum hydroxychloride (aluminum chloride) - the formation of sweat and be connected. Apart from the denaturation of the skin proteins, they work there for substances used, depending on their dosage, drastically in the heat in the armpit region and should only be used in exceptional cases the.
Durch die Verwendung antimikrobieller Stoffe in kosmetischen Desodorantien kann die Bakterienflora auf der Haut reduziert werden. Dabei sollten im Idealfalle nur die Geruch verursachenden Mikroorganismen wirksam reduziert werden. In der Praxis hat sich aber herausgestellt, daß die gesamte Mikroflora der Haut beeinträchtigt werden kann.By using antimicrobial substances in cosmetic deodorants, the Bacterial flora on the skin can be reduced. Ideally, only the smell causing microorganisms can be effectively reduced. In practice, however emphasized that the entire microflora of the skin can be affected.
Der Schweißfluß selbst wird dadurch nicht beeinflußt, im Idealfalle wird nur die mikro bielle Zersetzung des Schweißes zeitweilig gestoppt.The sweat flow itself is not affected by this, ideally only the micro Biological decomposition of the sweat temporarily stopped.
Auch die Kombination von Adstringentien mit antimikrobiell wirksamen Stoffen in ein und derselben Zusammensetzung ist gebräuchlich. Die Nachteile beider Wirkstoffklassen lassen sich auf diesem Wege jedoch nicht vollständig beseitigen.Also the combination of astringents with antimicrobial substances in one and the same composition is common. The disadvantages of both classes of active ingredients cannot be completely eliminated in this way.
Schließlich kann Körpergeruch auch durch Duftstoffe überdeckt werden, eine Methode, die am wenigsten den ästhetischen Bedürfnissen des Verbrauchers gerecht wird, da die Mischung aus Körpergeruch und Parfümduft eher unangenehm riecht.Finally, body odor can also be masked by fragrances, a method which least suits the aesthetic needs of the consumer since the Mixture of body odor and perfume smells rather unpleasant.
Allerdings werden die meisten kosmetischen Desodorantien, wie auch die meisten Kos metika insgesamt, parfümiert, selbst wenn sie desodorierende Wirkstoffe beinhalten. Parfümierung kann auch dazu dienen, die Verbraucherakzeptanz eines kosmetischen Produktes zu erhöhen oder einem Produkt ein bestimmtes Flair zu geben.However, most cosmetic deodorants, like most Kos Metika as a whole, scented, even if it contains deodorizing agents. Perfuming can also serve to improve consumer acceptance of a cosmetic To increase the product or to give a product a certain flair.
Die Parfümierung wirkstoffhaltiger kosmetischer Mittel, insbesondere kosmetischer Des odorantien, ist allerdings nicht selten problematisch, weil Wirkstoffe und Parfümbe standteile gelegentlich miteinander reagieren und einander unwirksam machen können.Perfuming cosmetic agents containing active ingredients, in particular cosmetic des odorants, however, is not infrequently problematic because of active ingredients and perfumes components occasionally react with one another and render each other ineffective.
Desodorantien sollen folgende Bedingungen erfüllen:
Deodorants should meet the following conditions:
- 1) Sie sollen eine zuverlässige Desodorierung bewirken.1) They should cause reliable deodorization.
- 2) Die natürlichen biologischen Vorgänge der Haut dürfen nicht durch die Desodo rantien beeinträchtigt werden.2) The natural biological processes of the skin must not be caused by the Desodo guarantees are affected.
- 3) Die Desodorantien müssen bei Überdosierung oder sonstiger nicht bestim mungsgemäßer Anwendung unschädlich sein.3) The deodorants do not have to be determined in the event of an overdose or other be harmless when used as directed.
- 4) Sie sollen sich nach wiederholter Anwendung nicht auf der Haut anreichern. 4) They should not accumulate on the skin after repeated use.
- 5) Sie sollen sich gut in übliche kosmetische Formulierungen einarbeiten lassen.5) They should be easy to incorporate into common cosmetic formulations.
Eine weitere Aufgabe der vorliegenden Erfindung war es also, kosmetische Desodoran tien zu entwickeln, die die Nachteile des Standes der Technik nicht aufweisen. Insbe sondere sollten die Desodorantien die Mikroflora der Haut weitgehend schonen, die Zahl der Mikroorganismen aber, die für den Körpergeruch verantwortlich sind, selektiv re duzieren.Another object of the present invention was therefore cosmetic deodorant tien develop that do not have the disadvantages of the prior art. In particular in particular, the deodorants should largely protect the microflora of the skin, the number of the microorganisms that are responsible for body odor, selectively re reduce.
Weiterhin war es eine Aufgabe der Erfindung, kosmetische Desodorantien zu entwic keln, die sich durch gute Hautverträglichkeit auszeichnen. Auf keinen Fall sollten die desodorierenden Wirkprinzipien sich auf der Haut anreichern.Furthermore, it was an object of the invention to develop cosmetic deodorants which are characterized by good skin tolerance. Under no circumstances should they deodorising principles accumulate on the skin.
Eine weitere Aufgabe war, kosmetische Desodorantien zu entwickeln, welche mit einer möglichst großen Vielzahl an üblichen kosmetischen Hilfs- und Zusatzstoffen harmonie ren, insbesondere mit den gerade in desodorierend oder antitranspirierend wirkenden Formulierungen bedeutenden Parfümbestandteilen.Another task was to develop cosmetic deodorants, which with a as large a variety of common cosmetic auxiliaries and additives as possible ren, especially those with a deodorant or antiperspirant effect Formulations of significant perfume ingredients.
Noch eine weitere Aufgabe der Erfindung war, kosmetische Desodorantien zur Verfü gung zu stellen, welche über einen längeren Zeitraum, und zwar in der Größenordnung von mindestens einem halben Tag, wirksam sind, ohne daß ihre Wirkung spürbar nach läßt.Yet another object of the invention was to provide cosmetic deodorants to ask, which over a longer period, in the order of magnitude of at least half a day, are effective without their effects noticeably after leaves.
Schließlich war eine Aufgabe der vorliegenden Erfindung, desodorierende kosmetische Prinzipien zu entwickeln, die möglichst universell in die verschiedensten Darreichungs formen kosmetischer Desodorantien eingearbeitet werden können, ohne auf eine oder wenige spezielle Darreichungsformen festgelegt zu sein.Finally, an object of the present invention was deodorant cosmetic Develop principles that are as universal as possible in a wide variety of dosage forms Shapes of cosmetic deodorants can be incorporated without having to take one or few special dosage forms.
Pilze, auch Fungi [fungus = lat. Pilz], Mycota [µνκηζ = grch. Pilz] oder Mycobionten ge nannt, zählen im Gegensatze zu den Bakterien zu den Eucaryonten. Eucaryonten sind Lebewesen, deren Zellen (Eucyten) im Gegensatz zu denen der sogenannten Proca ryonten (Procyten) über einen durch Kernhülle und Kernmembran vom restlichen Cyto plasma abgegrenzten Zellkern verfügen. Der Zellkern enthält die Erbinformation in Chro mosomen gespeichert. Mushrooms, also fungi [fungus = Latin mushroom], Mycota [µνκηζ = Greek mushroom] or Mycobionten ge in contrast to the bacteria are among the eucaryotes. Eucaryotes are Living beings whose cells (eucytes) are in contrast to those of the so-called proca ryonten (Procyten) through a nuclear envelope and core membrane from the rest of the Cyto plasma-delimited cell nucleus. The cell nucleus contains the genetic information in chro mosomes saved.
Zu Vertretern der Mycobionten zählen beispielsweise Hefen (Protoascornycetes), Schimmelpilze (Plectomycetes), Mehltau (Pyrenomycetes), der falsche Mehltau (Phyco mycetes) und die Ständerpilze (Basidiomycetes).Representatives of the mycobionts include, for example, yeasts (Protoascornycetes), Mold (Plectomycetes), powdery mildew (Pyrenomycetes), downy mildew (Phyco mycetes) and the mushrooms (Basidiomycetes).
Pilze, auch nicht die Basidiomyceten, sind keine pflanzlichen Organismen, haben aber wie diese eine Zellwand, zellsaftgefüllte Vakuolen und eine mikroskopisch gut sichtbare Plasmaströmung. Sie enthalten keine photosynthetischen Pigmente und sind C-hetero troph. Sie wachsen unter aeroben Bedingungen und gewinnen Energie durch Oxidation organischer Substanzen. Einige Vertreter, beispielsweise Hefen, sind allerdings fakulta tive Anaerobier und zur Energiegewinnung durch Gärungsprozesse befähigt.Fungi, not even the Basidiomycetes, are not plant organisms, but they do like this a cell wall, vacuoles filled with cell juice and a microscopic one that is clearly visible Plasma flow. They contain no photosynthetic pigments and are C-hetero troph. They grow under aerobic conditions and gain energy through oxidation organic substances. However, some representatives, such as yeasts, are facultative active anaerobes and capable of generating energy through fermentation processes.
Dermatomycosen sind Krankheiten, bei der gewisse Pilzarten, insbesondere Dermato phyten, in die Haut und Haarfollikel eindringen. Die Symptome von Dermatomycosen sind beispielsweise Bläschen, Exfoliation, Rhagaden und Erosion, meist verbunden mit Juckreiz oder allergischem Ekzem.Dermatomycoses are diseases in which certain types of fungi, especially dermatos phytes, penetrate the skin and hair follicles. The symptoms of dermatomycoses For example, vesicles, exfoliation, rhagades and erosion are usually associated with Itching or allergic eczema.
Dermatomycosen können im wesentlichen in folgende vier Gruppen unterteilt werden: Dermatophytien (z. B. Epidermophytie, Favus, Mikrosporie, Trichophytie), Hefemycosen (z. B. Pityriasis und andere Pityrosporum-bedingte Mycosen, Candida-Infektionen, Bla stomycose, Busse-Buschke-Krankheit, Torulose, Piedra alba, Torulopsidose, Trichospo rose), Schimmelmycosen (z. B. Aspergillose, Kephalosporidose, Phycomycose und Sko pulariopsidose), Systemmycosen (z. B. Chromomycose, Coccidiomycose, Histoplasmo se).Dermatomycoses can essentially be divided into the following four groups: Dermatophytia (e.g. epidermophytia, favus, microsporie, trichophytia), yeast mycoses (e.g. pityriasis and other pityrosporum-related mycoses, candida infections, Bla stomycose, Busse-Buschke disease, torulose, piedra alba, torulopsidosis, trichospo rose), mold mycoses (e.g. aspergillosis, cephalosporidosis, phycomycosis and Sko pulariopsidosis), system mycoses (e.g. chromomycosis, coccidiomycosis, histoplasmo se).
Zu den pathogenen und fakultativ pathogenen Keimen gehören beispielsweise aus der Gruppe der Hefen Candida-Arten (z. B. Candida albicans) und solche der Familie Pityro sporum. Pityrosporum-Arten, insbesondere Pityrosporum ovale, sind für Hauterkrankun gen wie Pityriasis versicolor, Seborrhoe in den formen Seborrhoea oleosa und Sebor rhoea sicca, welche sich vor allem als Seborrhoea capitis (= Kopfschuppen) äußern, se borrhoisches Ekzem und Pityrosporum-Follikulitis verantwortlich zu machen. Eine Betei ligung von Pityrosporum ovale an der Entstehung von Psoriasis wird von der Fachwelt diskutiert.Pathogenic and facultatively pathogenic germs include, for example, from Group of the yeast Candida species (e.g. Candida albicans) and those of the Pityro family sporum. Pityrosporum species, especially Pityrosporum oval, are for skin diseases genes like pityriasis versicolor, seborrhea in the forms seborrhoea oleosa and sebor rhoea sicca, which are mainly expressed as seborrhea capitis (= dandruff), se responsible for borrheic eczema and pityrosporum folliculitis. A beta Pityrosporum ovale's involvement in the development of psoriasis is recognized by experts discussed.
Alle Bereiche der menschlichen Haut können von Dermatomycosen befallen werden. Dermatophytien befallen fast ausschließlich Haut, Haare und Nägel. Hefemycosen kön nen auch Schleimhäute und innere Organe befallen, Systemmycosen erstrecken sich regelmäßig auf ganze Organsysteme.All areas of human skin can be affected by dermatomycoses. Dermatophytia almost exclusively affect skin, hair and nails. Hefemycoses can Mucous membranes and internal organs are also affected, systemic mycoses extend regularly on whole organ systems.
Besonders häufig sind die Körperbereiche betroffen, auf welchen sich durch Kleidung, Schmuck oder Schuhwerk Feuchtigkeit und Wärme stauen können. So gehört der Fuß pilz zu den bekanntesten und am weitesten verbreiteten Dermatomycosen. Besonders unangenehm sind weiterhin Pilzerkrankungen der Finger- und Fußnägelbereiche (Ony chomykosen).The areas of the body that are affected by clothing, Jewelry or shoes can accumulate moisture and heat. So the foot belongs mushroom to the best known and most widespread dermatomycoses. Especially fungal diseases of the finger and toenail areas are still unpleasant (Ony chomycoses).
Ferner sind Superinfektionen der Haut durch Pilze und Bakterien nicht selten.Furthermore, super infections of the skin by fungi and bacteria are not uncommon.
Bei bestehendem Primärinfekt, d. h., der normalen Keimbesiedelung der Haut, eintre tende Neuinfektion mit hohen Keimzahlen eines oder mehrerer oft physiologischer Erreger, beispielsweise Staphylokokken, oft aber auch unphysiologischer Erreger, beispielsweise Candida albicans, kann bei Zusammentreffen ungünstiger Einflüssen eine "Superinfektion" der befallenen Haut auftreten. Die normale Mikroflora der Haut (oder eines anderen Körperorgans) wird dabei von dem Sekundärerreger regelrecht überwuchert.If there is a primary infection, d. that is, the normal germ colonization of the skin Tending new infection with high bacterial counts of one or more often physiological Pathogens, for example staphylococci, but often also unphysiological pathogens, for example Candida albicans, can coincide with unfavorable influences a "super infection" of the affected skin may occur. The normal microflora of the skin (or another body organ) is literally caused by the secondary pathogen overgrown.
Solche Superinfektionen können sich, in Abhängigkeit vom betreffenden Keim, in günstig verlaufenden Fällen in unangenehmen Hauterscheinungen (Juckreiz, un schönes äußeres Erscheinungsbild) äußern. In ungünstig verlaufenden Fällen kön nen sie aber zu großflächiger Zerstörung der Haut führen, im schlimmsten Falle so gar im Tode des Patienten gipfeln.Such superinfections can, depending on the germ in question favorable cases in unpleasant skin symptoms (itching, un beautiful external appearance). In unfavorable cases, However, they can lead to extensive skin destruction, in the worst case culminate even in the patient's death.
Superinfektionen der vorab geschilderten Art sind z. B. beim Vollbild von AIDS häufig auftretende Sekundärerkrankungen. An sich - jedenfalls in geringen Keimdichten -un schädliche, aber unter Umständen auch ausgesprochen pathogene Keime überwu chern auf diese Weise die gesunde Hautflora. Bei AIDS allerdings sind auch andere Körperorgane von Superinfektionen betroffen.Superinfections of the type described above are e.g. B. often in the full screen of AIDS secondary diseases occurring. In itself - at least in low germ densities - we harmful, but possibly also extremely pathogenic germs In this way, the healthy skin flora is preserved. However, there are others with AIDS Body organs affected by super infections.
Ebenso werden derartige Superinfektionen bei einer Vielzahl dermatologischer Er krankungen, z. B. atopischem Ekzem, Neurodermitis, Akne, seborrhoischer Dermatitis oder Psoriasis beobachtet. Auch viele medizinische und therapeutische Maßnahmen, z. B. die Radio- oder Chemotherapie von Tumorerkrankungen, als Nebenwirkung her vorgerufene, medikamentös induzierte Immunsuppression oder aber systemische Antibiotikabehandlung, ebenso wie externe chemische oder physikalische Einflüsse (z. B. Umweltverschmutzung, Smog), fördern das Auftreten von Superinfektionen der äußeren und inneren Organe, insbesondere der Haut und der Schleimhäute.Such superinfections are also common in a variety of dermatological conditions diseases, e.g. B. atopic eczema, neurodermatitis, acne, seborrheic dermatitis or psoriasis is observed. Also many medical and therapeutic measures e.g. B. the radio or chemotherapy of tumor diseases, as a side effect Called, drug-induced immunosuppression or systemic Antibiotic treatment, as well as external chemical or physical influences (e.g. pollution, smog), promote the occurrence of super infections external and internal organs, especially the skin and mucous membranes.
Zwar ist es im Einzelfalle ohne weiteres möglich, Superinfektionen mit Antibiotika zu bekämpfen, meistens haben solche Substanzen aber den Nachteil unangenehmer Nebenwirkungen. Oft sind Patienten beispielsweise gegen Penicilline allergisch, wes wegen eine entsprechende Behandlung sich in einem solchen Falle verbieten würde.In individual cases, it is easily possible to prevent super infections with antibiotics combat, but mostly such substances have the disadvantage of being more unpleasant Side effects. For example, patients are often allergic to penicillins because appropriate treatment would be prohibited in such a case.
Ferner haben topisch verabreichte Antibiotika den Nachteil, daß sie die Hautflora nicht nur vom Sekundärerreger befreien, sondern auch die an sich physiologische Hautflora stark beeinträchtigen und der natürliche Heilungsprozeß auf diese Weise wieder gebremst wird.Furthermore, topically administered antibiotics have the disadvantage that they damage the skin flora not only rid of the secondary pathogen, but also the physiological itself Skin flora severely impair and the natural healing process in this way is braked again.
Aufgabe der vorliegenden Erfindung war, die Nachteile des Standes der Technik zu beseitigen und Substanzen und Zubereitungen, solche Substanzen enthaltend, zur Verfügung zu stellen, durch deren Verwendung Superinfektionen geheilt werden kön nen, wobei die physiologische Hautflora keine nennenswerte Einbußen erleidet.The object of the present invention was to overcome the disadvantages of the prior art eliminate and substances and preparations containing such substances for To make available, by using which super infections can be cured NEN, the physiological skin flora does not suffer any significant losses.
Protozoen sind parasitisch lebende Einzeller mit klar abgegrenztem Zellkern, die sich un
geschlechtlich fortpflanzen (durch Zwei- oder Vierfachteilung sowie Knospung), oder
aber geschlechtlich (Gameto-, Gamonto -und Autogamie). Die Nahrungsaufnahme aus
der Umgebung erfolgt durch Permeation sowie durch Pino- oder Phagozytose. Die
meisten Protozoen können neben vegetativen, meist beweglichen Zustandsformen
(sogenannten Trophozoiten) unter ungünstigen Umständen auch Zysten als Dauerfor
men ausbilden,
Je nach Fortbewegungsart und -apparat werden Protozoen in vier verschiedene Grup
pen unterteilt:
Protozoa are parasitic single-celled organisms with clearly delineated cell nuclei that reproduce sexlessly (by two or four division and budding), or sexually (Gameto, Gamonto and autogamy). The food is taken in from the environment by permeation as well as by pinocytosis or phagocytosis. In addition to vegetative, mostly mobile states (so-called trophozoites), most protozoa can also develop cysts as permanent forms under unfavorable circumstances,
Depending on the type and apparatus of locomotion, protozoa are divided into four different groups:
- (a) Mastigophora (Flagellaten mit Geißeln)(a) Mastigophora (flagellates with flagella)
- (b) Sarcodina/Rhizopoda (amöboides Bewegungsmuster durch Plasmaausstülpun gen)(b) Sarcodina / Rhizopoda (amoeboid movement pattern due to plasma protrusion gene)
- (c) Sporozoa (schlängelndes oder gleitendes Bewegungsmuster)(c) Sporozoa (meandering or sliding movement pattern)
- (d) Ciliata/Ciliophora (Bewimperung oder Begeißelung).(d) Ciliata / Ciliophora (cilia or flagellation).
Parasitisch lebende Protozoen werden in subtropischen und tropischen Gebieten häufig durch stechende und saugende Insekten, aber auch Schmutz- und Schmierinfektion so wie durch die Nahrungskette übertragen.Parasitic protozoa are common in subtropical and tropical areas through stinging and sucking insects, but also dirt and smear infection as transmitted through the food chain.
Einige medizinisch und dermatologisch relevante Protozoonosen sind: Trichomoniasis (verursacht von Trichomonas vaginalis), Lamblienruhr (verursacht durch Lamblia intesti nalis), viszerale sowie kutane und Schleimhaut-Leishmaniose (verursacht beispielsweise durch Leishmania donovanii, L. tropica, L. brasiliensis, L. mexicana, L. diffusa oder L. pi fanoi), Trypanosmiasis (verursacht durch verschiedene Trypanosoma-Arten), Amöben ruhr und Amöbiasis (verursacht beisielsweise durch verschiedene Entamoeba-Arten, Jo damoeba butschlii oder Naegleria fowleri), Kokzidose (durch Isospora belli) und Balantidenruhr (verursacht durch Balantidium coli).Some medically and dermatologically relevant protozoonoses are: trichomoniasis (caused by Trichomonas vaginalis), Lamblia dormancy (caused by Lamblia intesti nalis), visceral and cutaneous and mucosal leishmaniasis (causes, for example by Leishmania donovanii, L. tropica, L. brasiliensis, L. mexicana, L. diffusa or L. pi fanoi), trypanosmiasis (caused by different types of trypanosoma), amoebas ruhr and amoebiasis (caused, for example, by different types of Entamoeba, Jo damoeba butschlii or Naegleria fowleri), coccidosis (by Isospora belli) and Balantid dysentery (caused by Balantidium coli).
Durch Protozoonosen hervorgerufene medizinische und dermatologische Phänomene beeinträchtigen, zum Teil erhablich, das menschliche Wohlbefinden. Es besteht daher bei den betroffenen Personen ein erheblicher bedarf, diesem Zustande abzuhelfen. Eine Aufgabe der vorliegenden Erfindung war es also, gegen Protozoen wirksame Wirkprinzipien zu finden.Medical and dermatological phenomena caused by protozoonoses impair human well-being, in part considerable. It therefore exists the data subjects have a significant need to remedy this situation. An object of the present invention was therefore to act against protozoa To find active principles.
Parasiten [παρασ℩τοζ = grch. Tischgenosse, insb. Schmarotzer] sind ein- oder mehrzelli ge Pflanzen oder Tiere, die sich auf (= Ektoparasiten) oder in (= Endoparasiten) ande ren Lebewesen auf deren kosten ernähren, und zwar mit (= Pathogene Parasiten) oder ohne (Apathogene Parasiten) Verursachung von Krankheitserscheinungen. Die Lebens weise ist entweder auch aprophytisch oder aber rein parasitär, eventuell nur als pe riodischer, temporärer oder stationärer Parasit. Die Entwicklung von Parasiten ist an ei nen oder mehrere verschiedene Wirtsorgansimen gebunden, wobei der Mensch Zwi schenwirt oder Endwirt sein kann.Parasites [παρασ℩τοζ = grch. Table mate, esp. Parasite] are one or more cells plants or animals that are on (= ectoparasites) or in (= endoparasites) other nourish their creatures at their expense, with (= pathogenic parasites) or without (apathogenic parasites) causing symptoms. The life Wise is either aprophytic or purely parasitic, possibly only as a pe periodic, temporary or stationary parasite. The development of parasites is on egg NEN or more different host organisms bound, the human Zwi may be a host or end host.
Medizinisch und dermatologisch bedeutsame Parasiten sind beispielsweise die Helmin then, die sich wiederum in Trematodae, Cestodae und Nematodae untergliedern. Das menschliche Wohlbefinden beeinträchtigende Helminthosen sind beispielsweise Bilhar ziose, (verursacht durch Schistosoma-Arten), Bandwurmbefall vom Darm und anderen inneren Organen (verursacht durch beispielsweise Taenia-Arten und Echinococcus-Ar ten), Ascariasis (verursacht durch Ascaris lumbricoides), Enterobiasis (verursacht durch Enterobium vermicularis), Paragonimiasis (verursacht durch Paragonium-Arten), Filari ose (verursacht beispielsweise durch Wucheria bancrofti) sowie anderer Nematodenbe fall (beispielsweise verursacht durch Trichuris trichura oder Trichinella spiralis).Helmin are examples of medically and dermatologically significant parasites then, which in turn are divided into Trematodae, Cestodae and Nematodae. The Helmet pants that impair human well-being are, for example, Bilhar ziosis, (caused by Schistosoma species), tapeworm infestation from the intestine and others internal organs (caused by e.g. Taenia species and Echinococcus-Ar ten), Ascariasis (caused by Ascaris lumbricoides), Enterobiasis (caused by Enterobium vermicularis), Paragonimiasis (caused by Paragonium species), Filari ose (caused, for example, by Wucheria bancrofti) and other nematode bees case (for example caused by Trichuris trichura or Trichinella spiralis).
Darüberhinaus bestehen eine Vielzahl auf bzw. in Mensch und Tier parasitisch lebender Insektenarten bzw. Spinnentieren, die medizinische und dermatologische Veränderun gen der Wirtsorganismen hervorrufen. In dieser Hinsicht für die Beeinträchtigung des menschlichen Wohlbefindens verantwortliche Parasitosen sind beispielsweise Accro dermatitis (verursacht durch Getreidemilben, beispielsweise Pediculoides ventricosus), Skabies (verursacht durch Sarcoptes scabii), Fliegen- und/oder Fliegenlarvenbefall (verursacht beispielsweise durch Glossina-, Stomoxys-, Tabanus-, Chrysops-, Lucilia-, Chrysomya-, Cochliamya-, Wohlfartia-, Cordylobia- oder Dermatobia-Arten), Mücken- und/oder Mückenlarvenbefall (verursacht beispielsweise durch Aedes- Culex-, Ano pheles-, Phlebotomus-, Culicuides-, Sumilium- oder Haemagoges-Arten), Zeckenbefall (verursacht beispielsweise durch Argas persicus und andere Argas-Arten, Ornithodorus erraticus und andere Ornithodorus-Arten, Orobius- Rhiphocephalus-, Dermacentor-, Haemaphysalis-, Amblyomma-, Ixodes-Arten), Porocephalose (verursacht durch Po rocephalus-Arten), Flohbefall (verursacht durch beispielsweise Pulex irrttans, Ctenoce phalides canis, Xenopsylla cheopsis, Nosophyllus fasciatus oder Sarcopsylla pene trans), Läusebefall (verursacht beispielsweise durch Phthirius pubis, Pediculosus huma nus oder Pediculosus captits), Wanzenbefall (verursacht beispielsweise durch Cimex lectularius, Cimex hemipterus, Panstrongylus megistus, Rhodnius prolixus, Triatoma dimidata, Triatoma infestans, Triatoma sordida oder Triatoma brasiliensis) sowie Mil benbefall (verursacht beispielsweise durch Demodex folliculorum und andere Demodex- Arten sowie durch Dermamyskus-Arten, Glyciphagus domesticus, Pyemotes-Arten, Sar coptes-Arten oder Trombicula-Arten).In addition, there are a large number of parasitic species on or in humans and animals Insect species or arachnids, the medical and dermatological changes against the host organisms. In this regard, for the impairment of the Parasitosis responsible for human well-being are, for example, Accro dermatitis (caused by cereal mites, e.g. Pediculoides ventricosus), Scabies (caused by Sarcoptes scabii), fly and / or fly larvae (caused, for example, by Glossina, Stomoxys, Tabanus, Chrysops, Lucilia, Chrysomya, Cochliamya, Wohlfartia, Cordylobia or Dermatobia species), mosquito and / or Mosquito larvae infestation (caused, for example, by Aedes- Culex-, Ano pheles, phlebotomus, culicuides, sumilium or haemagoges species), tick infestation (caused, for example, by Argas persicus and other Argas species, Ornithodorus erraticus and other Ornithodorus species, Orobius Rhiphocephalus, Dermacentor, Haemaphysalis, Amblyomma, Ixodes species), Porocephalose (caused by Po rocephalus species), flea infestation (caused, for example, by Pulex irrttans, Ctenoce phalides canis, Xenopsylla cheopsis, Nosophyllus fasciatus or Sarcopsylla pene trans), lice infestation (caused, for example, by Phthirius pubis, Pediculosus huma nus or Pediculosus captits), bug infestation (caused, for example, by Cimex lectularius, Cimex hemipterus, Panstrongylus megistus, Rhodnius prolixus, Triatoma dimidata, Triatoma infestans, Triatoma sordida or Triatoma brasiliensis) and Mil infestation (caused, for example, by Demodex folliculorum and other Demodex Species as well as by Dermamyskus species, Glyciphagus domesticus, Pyemotes species, Sar coptes species or Trombicula species).
Dabei ist von zusätzlicher Bedeutung, daß die auf oder im menschlichen Organismus le benden Parasiten ihrerseits wieder Überträger von Bakterien, Mycota, Protozoen und Vi ren sein können, die Gesundheit und Wohlbefinden des Wirtsorganismus, beispielswei se des Menschen, nachhaltig beeinträchtigen können. Es bestand daher der Bedarf, gegen Parasitosen wirksame Wirkprinzipien zu finden, welche das medizinische oder dermatologische Erscheinungsbild zu verbessern imstande sind. Diesen Bedarf zu stil len, war daher eine weitere Aufgabe der vorliegenden Erfindung.It is of additional importance that the le on or in the human organism parasites in turn transmit bacteria, mycota, protozoa and vi the health and well-being of the host organism, for example of human beings, can have a lasting impact. There was therefore a need to find active principles effective against parasitoses, which the medical or are able to improve the dermatological appearance. To style this need len was therefore another object of the present invention.
Im Gegensatze zu den prokaryotischen und eukaryotischen zellulären Organismen sind Viren [virus = lat. Gift] biologische Strukturen, welche zur Biosynthese eine Wirtszelle benötigen. Extrazelluläre Viren (auch "Virionen" genannt) bestehen aus ei ner ein- oder doppelsträngigen Nukleinsäuresequenz (DNS oder RNS) und einem Proteinmantel (Capsid genannt), gegebenenfalls einer zusätzlichen lipidhaltigen Hülle (Envelope) umgeben. Die Gesamtheit aus Nukleinsäure und Capsid wird auch Nu cleocapsid genannt. Die Klassifikation der Viren erfolgte klassisch nach klinischen Kriterien, heutzutage allerdings zumeist nach ihrer Struktur, ihrer Morphologie, insbe sondere aber nach der Nukleinsäuresequenz.In contrast to the prokaryotic and eukaryotic cellular organisms are viruses [virus = lat. poison] biological structures which are essential for biosynthesis Need host cell. Extracellular viruses (also called "virions") consist of egg ner single or double stranded nucleic acid sequence (DNA or RNA) and one Protein coat (called capsid), optionally an additional lipid-containing shell (Envelope) surrounded. The whole of nucleic acid and capsid is also Nu called cleocapsid. The viruses were classified classically according to clinical ones Criteria, nowadays mostly according to their structure, their morphology, in particular but especially after the nucleic acid sequence.
Medizinisch wichtige Virengattungen sind beispielsweise Influenzaviren (Familie der Orthomyxoviridae), Lyssaviren (z. B. Tollwut, Familie der Rhabdoviren) Enteroviren (z. B. Hepatitis-A, Familie der Picornaviridae), Hepadnaviren (z. B. Hepatitis-B, Familie der Hepadnaviridae).Medically important virus types are, for example, influenza viruses (family of the Orthomyxoviridae), lyssaviruses (e.g. rabies, family of rhabdoviruses) enteroviruses (e.g. hepatitis A, family of the Picornaviridae), hepadnaviruses (e.g. hepatitis B, family the Hepadnaviridae).
Viruzide, also Viren abtötende Substanzen im eigentlichen Sinne gibt es nicht, da Vi ren nicht über eigenen Stoffwechsel verfügen. Es wurde aus diesem Grunde auch diskutiert, ob Viren als Lebewesen eingeordnet werden sollten. Pharmakologische Eingriffe ohne Schädigung der nicht befallenen Zellen ist jedenfalls schwierig. Mögli che Wirkmechanismen im Kampfe gegen die Viren sind in erster Linie die Störung deren Replikation, z. B. durch Blockieren der für die Replikation wichtigen Enzyme, die in der Wirtszelle vorliegen. Ferner kann das Freisetzen der viralen Nukleinsäuren in die Wirtszelle verhindert werden. Im Rahmen der hiermit vorgelegten Offenbarung wird unter Begriffen wie "antiviral" oder "gegen Viren wirksam", "viruzid" oder ähnli chen die Eigenschaft einer Substanz verstanden, einen ein- oder mehrzelligen Orga nismus vor schädlichen Folgen einer Virusinfektion, sei es prophylaktisch oder thera peutisch, zu schützen, ungeachtet dessen, was der tatsächliche Wirkmechanismus der Substanz im Einzelfalle sei.There are no virucides, i.e. virus-killing substances in the actual sense, since Vi do not have their own metabolism. It was for that reason too discusses whether viruses should be classified as living beings. Pharmacological Interventions without damage to the unaffected cells is difficult in any case. Possible Mechanisms of action in the fight against viruses are primarily the disruption their replication, e.g. B. by blocking the enzymes important for replication, that are present in the host cell. Furthermore, the release of the viral nucleic acids be prevented into the host cell. As part of the disclosure presented herewith is used under terms such as "antiviral" or "effective against viruses", "virucidal" or similar understood the property of a substance, a single or multi-cell organization against harmful consequences of a viral infection, be it prophylactic or thera peutisch, to protect, regardless of what the actual mechanism of action of the substance in individual cases.
Dem Stande der Technik mangelt es jedoch an gegen Viren wirksamen Substanzen, welche zudem den Wirtsorganismus nicht oder nicht in vertretbarem Maße schädi gen.However, the prior art lacks substances which are active against viruses, which, moreover, does not harm the host organism or does not do so to an acceptable degree gene.
Eine Aufgabe der vorliegenden Erfindung war also, diesem Übelstande abzuhelfen, also Substanzen zu finden, welche wirksam einen ein- oder mehrzelligen Organismus vor schädlichen Folgen einer Virusinfektion, sei es prophylaktisch oder therapeutisch, zu schützen. An object of the present invention was therefore to remedy this problem, So to find substances that are effective in a single or multicellular organism against harmful consequences of a viral infection, be it prophylactic or therapeutic, to protect.
Es wurde überraschend gefunden, und darin liegt die Lösung all dieser Aufgaben, daß
die Verwendung von Estern gemäß der Formel
It has surprisingly been found and the solution to all these problems is that the use of esters according to the formula
wobei R1, R2, R3 und R4 unabhängig voneinander gewählt werden aus der Gruppe der verzweigten oder unverzweigten Alkylreste mit 1-24 Kohlenstoffatomen und n und m unabhängig voneinander Zahlen von 0 bis 24 darstellen, als antibakterielle, antimyco tische, antiparasitäre oder antivirale Wirkstoffe, den Nachteilen des Standes der Technik abhilft.where R 1 , R 2 , R 3 and R 4 are independently selected from the group of branched or unbranched alkyl radicals having 1-24 carbon atoms and n and m independently of one another are numbers from 0 to 24, as antibacterial, antimycotic, antiparasitic or antiviral active ingredients which remedies the disadvantages of the prior art.
Vorteilhaft werden die Alkylreste so gewählt daß
R1 = 2-6
R2 = 4-8
R3 = 2-6
R4 = 4-8
Weiter vorteilhaft wird n aus dem Bereich von 0-10 gewählt.The alkyl radicals are advantageously chosen so that
R 1 = 2-6
R 2 = 4-8
R 3 = 2-6
R 4 = 4-8
N is advantageously selected from the range from 0-10.
Insbesondere vorteilhaft ist, die den erfindungsgemäßen Estern zugrundeliegenden alkylierten Carbonsäuren aus der Gruppe der 2-Alkyl-Carbonsäuren zu wählen.It is particularly advantageous to base the esters according to the invention to choose alkylated carboxylic acids from the group of 2-alkyl carboxylic acids.
Bevorzugt sind insbesondere 2-Ethylhexansäure-2-ethylhexanoat, 2-Butyloctyl-2-butyl octanoat, 2-Butyloctyl-2-butyldecanoat, 2-Butyloctyl-2-hexyldecanoat, 2-Butyloctyl-2- octyldodecanoat, Isotridecylisononanoat, 2-Hexyldecyl-2-octyldodecanoat, 2-Butylde cyl-2-octyldecanoat, Isodecylisononanoat.2-Ethylhexanoic acid-2-ethylhexanoate, 2-butyloctyl-2-butyl are particularly preferred octanoate, 2-butyloctyl-2-butyldecanoate, 2-butyloctyl-2-hexyldecanoate, 2-butyloctyl-2- octyldodecanoate, isotridecylisononanoate, 2-hexyldecyl-2-octyldodecanoate, 2-butylde cyl-2-octyl decanoate, isodecyl isononanoate.
Es hat sich in erstaunlicher Weise herausgestellt, daß die erfindungsgemäß verwende ten Ester das Wachstum von grampositiven und gramnegativen Bakterien, Myco bionten sowie Viren verhindern. It has surprisingly been found that the use according to the invention esters the growth of gram-positive and gram-negative bacteria, Myco prevent bionts and viruses.
Insbesondere sind die erfindungsgemäß verwendeten Ester befähigt, das Wachstum von Hefen, insbesondere der Pityrosporum-Arten, namentlich Pityrosporum ovale, zu verhindern.In particular, the esters used according to the invention are capable of growth of yeasts, in particular of the Pityrosporum species, namely Pityrosporum ovale prevent.
Es hat sich ferner herausgestellt, daß die erfindungsgemäß verwendeten Ester die Bil dung von seborrhoischen Erscheinungen, insbesondere Kopfschuppen, verhindern so wie bereits vorhandene seborrhoische Erscheinungen, insbesondere Kopfschuppen, zu beseitigen.It has also been found that the esters used in the invention the Bil This prevents the development of seborrheic symptoms, especially dandruff like existing seborrheic phenomena, especially dandruff, to eliminate.
Die erfindungsgemäß verwendeten Ester eignen sich darüberhinaus gut für die Ver wendung als desodorierender Wirkstoff in kosmetischen Desodorantien sowie gegen unreine Haut, leichte Formen der Akne bzw. Propionibakterium acnes.The esters used according to the invention are moreover suitable for the Ver use as a deodorant active ingredient in cosmetic deodorants and against impure skin, mild forms of acne or propionibacterium acnes.
Schließlich hat sich herausgestellt, daß die erfindungsgemäß verwendeten Ester den Verderb organischer Substanz, insbesondere kosmetischer und dermatologischer Zu bereitungen, durch den Befall mit grampositiven und gramnegativen Bakterien, My cobionten und Viren verhindern können, wenn sie diesen Zubereitungen zugesetzt werden.Finally, it has been found that the esters used according to the invention are the Spoilage of organic matter, especially cosmetic and dermatological additives preparations, by infestation with gram-positive and gram-negative bacteria, My can prevent cobionts and viruses if added to these preparations will.
Erfindungsgemäß sind somit auch ein Verfahren zur Bekämpfung von Mycobionten,
dadurch gekennzeichnet, daß von Estern gemäß der Formel
According to the invention are thus also a method for combating mycobionts, characterized in that of esters according to the formula
wobei R1, R2, R3 und R4 unabhängig voneinander gewählt werden aus der Gruppe der
verzweigten oder unverzweigten Alkylreste mit 1-24 Kohlenstoffatomen und n und m
unabhängig voneinander Zahlen von 0 bis 24 darstellen, gegebenenfalls in einem ge
eigneten kosmetischen oder dermatologischen Träger, mit dem durch Mycobionten
kontaminierten Bereich in Kontakt gebracht werden, sowie ein Verfahren zum Schutze
organischer Produkte vor dem Befall mit Mycobionten, dadurch gekennzeichnet, daß
diesen organischen Produkten Ester gemäß der Formel
wherein R 1 , R 2 , R 3 and R 4 are independently selected from the group of branched or unbranched alkyl radicals having 1-24 carbon atoms and n and m independently of one another are numbers from 0 to 24, optionally in a suitable cosmetic or dermatological Carrier with which the area contaminated by mycobionts is brought into contact, and a method for protecting organic products from attack by mycobionts, characterized in that these organic products have esters according to the formula
wobei R1, R2, R3 und R4 unabhängig voneinander gewählt werden aus der Gruppe der verzweigten oder unverzweigten Alkylreste mit 1-24 Kohlenstoffatomen und n und m unabhängig voneinander Zahlen von 0 bis 24 darstellen, in wirksamer Menge zugege ben werden.where R 1 , R 2 , R 3 and R 4 are selected independently of one another from the group of branched or unbranched alkyl radicals having 1-24 carbon atoms and n and m independently of one another are numbers from 0 to 24, are added in an effective amount.
Zwar beschreit die DE-OS 195 16 705 die Verwendung dialkylsubstituierter Essigsäu ren als antibakterielle, antimycotische oder antivirale Wirkstoffe. Sie konnte aber nicht den Weg zur vorliegenden Erfindung bahnen.DE-OS 195 16 705 describes the use of dialkyl-substituted acetic acid as antibacterial, antimycotic or antiviral agents. But she couldn't pave the way to the present invention.
Es war erstaunlich, daß die erfindungsgemäß verwendeten Ester besonders gut wirk sam sind gegen den für das Entstehen von Kopfschuppen verantwortlichen Keim Pity rosporum ovale und verwandte Keime. Eine bevorzugte Ausführungsform der vorlie genden Erfindung sind mithin gegen Kopfschuppen anzuwendende Formulierungen, beispielsweise Antischuppenshampoos.It was surprising that the esters used according to the invention work particularly well sam are against the germ pity responsible for the development of dandruff rosporum oval and related germs. A preferred embodiment of the present formulations to be used against dandruff, for example anti-dandruff shampoos.
Erfindungsgemäß werden die erfindungsgemäß verwendeten Ester bevorzugt in kos metischen oder dermatologischen Zusammensetzungen eingesetzt einem Gehalt von 0,005-50,0 Gew.-%, insbesondere 0,01-20,0 Gew.-%, bezogen auf das Gesamtge wicht der Zusammensetzung bevorzugt sind. Vorteilhaft enthalten die Zusammenset zungen 0,02-10,0 Gew.-%, besonders bevorzugt 0,02-5,0 Gew.-% an den erfin dungsgemäß verwendeten Estern, ganz besonders vorteilhaft 0,5-3,0 Gew.-%, je weils bezogen auf das Gesamtgewicht der Zusammensetzung.According to the invention, the esters used according to the invention are preferably in kos metallic or dermatological compositions used 0.005-50.0 wt .-%, in particular 0.01-20.0 wt .-%, based on the total Ge importance of the composition are preferred. The sets advantageously contain tongues 0.02-10.0 wt .-%, particularly preferably 0.02-5.0 wt .-% of the inventions esters used according to the invention, very particularly advantageously 0.5-3.0% by weight, each Weil based on the total weight of the composition.
Es ist auch von Vorteil, anstatt reiner erfindungsgemäßer dialkylsubstituierter Carbon säureester solche Stoffe zu verwenden, welche sich ihrerseits durch einen Gehalt an erfindungsgemäß verwendeten Estern auszeichnen.It is also advantageous instead of pure dialkyl-substituted carbon according to the invention acid esters to use such substances, which in turn are characterized by a content of Distinct esters used according to the invention.
Die erfindungsgemäß verwendeten Ester lassen sich ohne Schwierigkeiten in gängige kosmetische oder dermatologische Formulierungen einarbeiten, vorteilhaft in Pump sprays, Aerosolsprays, Cremes, Salben, Tinkturen, Lotionen, Nagelpflegeprodukte (z. B. Nagellacke, Nagellackentferner, Nagelbalsame) und dergleichen.The esters used according to the invention can easily be converted into common ones Incorporate cosmetic or dermatological formulations, advantageously in Pump sprays, aerosol sprays, creams, ointments, tinctures, lotions, nail care products (e.g. nail polishes, nail polish remover, nail balms) and the like.
Ganz besonders vorteilhaft liegen die erfindungsgemäß verwendeten Ester in Form von Antischuppen-Shampoos vor.The esters used according to the invention are very particularly advantageously in the form of anti-dandruff shampoos.
Es ist auch möglich und gegebenenfalls vorteilhaft, die erfindungsgemäß verwendeten Ester mit anderen Wirkstoffen zu kombinieren, beispielsweise mit anderen antimikro biell, antimycotisch, antiparasitär bzw. antiviral wirksamen Stoffen.It is also possible and possibly advantageous to use those used in accordance with the invention Combine esters with other active ingredients, for example with other antimicro biological, antimycotic, antiparasitic or antiviral substances.
Es ist vorteilhaft, die Zusammensetzungen gemäß der Erfindung abzupuffern. Vorteil haft ist ein pH-Bereich von 3,5-7,5. Besonders günstig ist es, den pH-Wert in einem Bereich von 4,0-6,5 zu wählen.It is advantageous to buffer the compositions according to the invention. Advantage is a pH range of 3.5-7.5. It is particularly beneficial to have the pH in one Range from 4.0-6.5 to choose.
Die kosmetischen und/oder dermatologischen Formulierungen gemäß der Erfindung können wie üblich zusammengesetzt sein und zur Behandlung der Haut und/oder der Haare im Sinne einer dermatologischen Behandlung oder einer Behandlung im Sinne der pflegenden Kosmetik dienen. Sie können aber auch in Schminkprodukten in der dekorativen Kosmetik eingesetzt werden.The cosmetic and / or dermatological formulations according to the invention can be composed as usual and for the treatment of the skin and / or Hair in the sense of a dermatological treatment or a treatment in the sense serve the nourishing cosmetics. But you can also in make-up products in the decorative cosmetics are used.
Zur Anwendung werden die kosmetischen und/oder dermatologischen Formulierungen gemäß der Erfindung in der für Kosmetika und Dermatika üblichen Weise auf die Haut und/oder die Haare in ausreichender Menge aufgebracht.The cosmetic and / or dermatological formulations are used according to the invention in the usual manner for cosmetics and dermatics on the skin and / or the hair is applied in sufficient quantity.
Vorteilhaft sind solche kosmetische und dermatologische Zubereitungen, die in der Form eines Sonnenschutzmittels vorliegen. Vorteilhaft enthalten diese zusätzlich min destens einen UVA-Filter und/oder mindestens einen UVB-Filter und/oder mindestens ein anorganisches Pigment.Cosmetic and dermatological preparations which are advantageous in the Form of a sunscreen. These advantageously also contain min at least one UVA filter and / or at least one UVB filter and / or at least an inorganic pigment.
Kosmetische Zubereitungen gemäß der Erfindung zum Schutze der Haut vor UV- Strahlen können in verschiedenen Formen vorliegen, wie sie z. B. üblicherweise für die sen Typ von Zubereitungen eingesetzt werden. So können sie z. B. eine Lösung, eine Emulsion vom Typ Wasser-in-Öl (W/O) oder vom Typ Öl-in-Wasser (O/W), oder eine multiple Emulsionen, beispielsweise vom Typ Wasser-in-Öl-in-Wasser (W/O/W), ein Gel, eine Hydrodispersion, einen festen Stift oder auch ein Aerosol darstellen. Cosmetic preparations according to the invention for protecting the skin against UV Rays can be in various forms, such as those found in B. usually for sen type of preparations can be used. So you can z. B. a solution, a Water-in-oil (W / O) or oil-in-water (O / W) type emulsion, or a multiple emulsions, for example of the water-in-oil-in-water (W / O / W) type Gel, a hydrodispersion, a solid stick or an aerosol.
Die kosmetischen Zubereitungen gemäß der Erfindung können kosmetische Hilfsstoffe enthalten, wie sie üblicherweise in solchen Zubereitungen verwendet werden, z. B. Konservierungsmittel, Bakterizide, Antioxidantien, Parfüme, Mittel zum Verhindern des Schäumens, Farbstoffe, Pigmente, die eine färbende Wirkung haben, Verdickungsmit tel, oberflächenaktive Substanzen, Emulgatoren, weichmachende Substanzen, an feuchtende und/oder feuchthaltende Substanzen, Fette, Öle, Wachse oder andere übli che Bestandteile einer kosmetischen Formulierung wie Alkohole, Polyole, Polymere, Schaumstabilisatoren, Elektrolyte, organische Lösungsmittel oder Silikonderivate.The cosmetic preparations according to the invention can be cosmetic auxiliaries contain, as they are usually used in such preparations, for. B. Preservatives, bactericides, antioxidants, perfumes, agents for preventing the Foaming, dyes, pigments that have a coloring effect, thickening agent tel, surface-active substances, emulsifiers, softening substances moist and / or moisturizing substances, fats, oils, waxes or other common constituents of a cosmetic formulation such as alcohols, polyols, polymers, Foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Sofern die kosmetische oder dermatologische Zubereitung eine Lösung oder Lotion
darstellt, können als Lösungsmittel verwendet werden:
If the cosmetic or dermatological preparation is a solution or lotion, the following can be used as solvents:
- - Wasser oder wäßrige Lösungen;- water or aqueous solutions;
- - Öle, wie Triglyceride der Caprin- oder der Caprylsäure, vorzugsweise aber Rizi nusöl;- Oils, such as triglycerides of capric or caprylic acid, but preferably Rizi nut oil;
- - Fette, Wachse und andere natürliche und synthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z. B. mit Isopropanol, Propy lenglykol oder Glycerin, oder Ester von Fettalkoholen mit Alkansäuren niedriger C-Zahl oder mit Fettsäuren;- Fats, waxes and other natural and synthetic fat bodies, preferably Esters of fatty acids with low C alcohols, e.g. B. with isopropanol, propy lenglycol or glycerin, or lower esters of fatty alcohols with alkanoic acids C number or with fatty acids;
- - Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Ethanol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol, Ethylenglykolmo noethyl- oder -monobutylether, Propylenglykolmonomethyl, -monoethyl- oder -monobutylether, Diethylenglykolmonomethyl- oder -monoethylether und analoge Produkte.- Alcohols, diols or polyols of low C number, and their ethers, preferably Ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol mo noethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or -monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analog Products.
Insbesondere werden Gemische der vorstehend genannten Lösungsmittel verwendet. Bei alkoholischen Lösungsmitteln kann Wasser ein weiterer Bestandteil sein.Mixtures of the abovementioned solvents are used in particular. Water can also be a component of alcoholic solvents.
Erfindungsgemäß können als günstige Antioxidantien alle für kosmetische und/oder dermatologische Anwendungen geeigneten oder gebräuchlichen Antioxidantien ver wendet werden.According to the invention, all of the cosmetic and / or dermatological applications suitable or customary antioxidants ver be applied.
Vorteilhaft werden die Antioxidantien gewählt aus der Gruppe bestehend aus Amino säuren (z. B. Glycin, Histidin, Tyrosin, Tryptophan) und deren Derivate, Imidazole (z. B. Urocaninsäure) und deren Derivate, Peptide wie D,L-Carnosin, D-Carnosin, L-Camosin und deren Derivate (z. B. Anserin), Carotinoide, Carotine (z. B. α-Carotin, p-Carotin, Ly copin) und deren Derivate, Liponsäure und deren Derivate (z. B. Dihydroliponsäure), Aurothioglucose, Propylthiouracil und andere Thiole (z. B. Thioredoxin, Glutathion, Cy stein, Cystin, Cystamin und deren Glycosyl-, N-Acetyl-, Methyl-, Ethyl-, Propyl-, Amyl-, Butyl- und Lauryl-, Palmitoyl-, Oleyl-, γ-Linoleyl-, Cholesteryl - und Glycerylester) sowie deren Salze, Dilaurylthiodipropionat, Distearylthiodipropionat, Thiodipropionsäure und deren Derivate (Ester, Ether, Peptide, Lipide, Nukleotide, Nukleoside und Salze) sowie Sulfoximinverbindungen (z. B. Buthioninsulfoximine, Homocysteinsulfoximin, Buthionin sulfone, Penta-, Hexa-, Heptathioninsulfoximin) in sehr geringen verträglichen Dosie rungen (z. B. pmol bis µmol/kg), ferner (Metall)-Chelatoren (z. B. α-Hydroxyfettsäuren, Palmitinsäure, Phytinsäure, Lactoferrin), α-Hydroxysäuren (z. B. Zitronensäure, Milch säure, Apfelsäure), Huminsäure, Gallensäure, Gallenextrakte, Bilirubin, Biliverdin, EDTA, EGTA und deren Derivate, ungesättigte Fettsäuren und deren Derivate (z. B. γ- Linolensäure, Linolsäure, Ölsäure), Folsäure und deren Derivate, Ubichinon und Ubi chinol und deren Derivate, Vitamin C und Derivate (z. B. Ascorbylpalmitat, Mg-Ascor bylphosphat, Ascorbylacetat), Tocopherole und Derivate (z. B. Vitamin E-acetat), Vita min A und Derivate (Vitamin A-palmitat) sowie Konyferylbenzoat des Benzoeharzes, Rutinsäure und deren Derivate, Ferulasäure und deren Derivate, Butylhydroxytoluol, Butylhydroxyanisol, Nordihydroguajakharzsäure, Nordihydroguajaretsäure, Trihydroxy butyrophenon, Harnsäure und deren Derivate, Mannose und deren Derivate, Zink und dessen Derivate (z. B. ZnO, ZnSO4) Selen und dessen Derivate (z. B. Selenmethionin), Stilbene und deren Derivate (z. B. Stilbenoxid, Trans-Stilbenoxid) und die erfindungsge mäß geeigneten Derivate (Salze, Ester, Ether, Zucker, Nukleotide, Nukleoside, Peptide und Lipide) dieser genannten Wirkstoffe.The antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D. -Carnosine, L-camosine and their derivatives (e.g. Anserin), carotenoids, carotenes (e.g. α-carotene, p-carotene, Ly copin) and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid ), Aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cystine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl) , Palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (e.g. Buthionine sulfoximines, homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathionine sulfoximides n) in very low tolerable dosages (e.g. B. pmol to µmol / kg), also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid , Biliary extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g. γ-linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg-Ascor byl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) as well as konyferyl benzoate of benzoin, rutinic acid and its derivatives, Ferulic acid and its derivatives, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxy butyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (e.g. ZnO, ZnSO 4 ) selenium and its derivatives (e.g. selenium ), P tilbene and their derivatives (e.g. As stilbene oxide, trans-stilbene oxide) and the derivatives according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances.
Die Menge der Antioxidantien (eine oder mehrere Verbindungen) in den Zubereitungen beträgt vorzugsweise 0,001 bis 30 Gew.-%, besonders bevorzugt 0,05-20 Gew.-%, insbesondere 1-10 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitung.The amount of antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10 wt .-%, based on the total weight of the preparation.
Sofern Vitamin E und/oder dessen Derivate das oder die Antioxidantien darstellen, ist vorteilhaft, deren jeweilige Konzentrationen aus dem Bereich von 0,001-10 Gew.-%, bezogen auf das Gesamtgewicht der Formulierung, zu wählen.If vitamin E and / or its derivatives are the antioxidant (s) advantageous, their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation.
Sofern Vitamin A, bzw. Vitamin-A-Derivate, bzw. Carotine bzw. deren Derivate das oder die Antioxidantien darstellen, ist vorteilhaft, deren jeweilige Konzentrationen aus dem Bereich von 0,001-10 Gew.-%, bezogen auf das Gesamtgewicht der Formulie rung, zu wählen. If vitamin A, or vitamin A derivatives, or carotenes or their derivatives, the or which are antioxidants, is advantageous in their respective concentrations the range of 0.001-10% by weight based on the total weight of the formulation tion to choose.
Emulsionen sind gemäß der Erfindung vorteilhaft und enthalten z. B. die genannten Fette, Öle, Wachse und anderen Fettkörper, sowie Wasser und einen Emulgator, wie er üblicherweise für einen solchen Typ der Formulierung verwendet wird.Emulsions are advantageous according to the invention and contain z. B. the above Fats, oils, waxes and other fat bodies, as well as water and an emulsifier, such as it is commonly used for such a type of formulation.
Gele gemäß der Erfindung enthalten üblicherweise Alkohole niedriger C-Zahl, z. B. Ethanol, Isopropanol, 1,2-Propandiol, Glycerin und Wasser bzw. ein vorstehend ge nanntes Öl in Gegenwart eines Verdickungsmittels, das bei ölig-alkoholischen Gelen vorzugsweise Siliciumdioxid oder ein Aluminiumsilikat, bei wäßrig-alkoholischen oder alkoholischen Gelen vorzugsweise ein Polyacrylat ist.Gels according to the invention usually contain low C number alcohols, e.g. B. Ethanol, isopropanol, 1,2-propanediol, glycerin and water or a ge above named oil in the presence of a thickening agent used in oily alcoholic gels preferably silicon dioxide or an aluminum silicate, in the case of aqueous alcoholic or alcoholic gels is preferably a polyacrylate.
Feste Stifte gemäß der Erfindung enthalten z. B. natürliche oder synthetische Wachse, Fettalkohole oder Fettsäureester. Bevorzugt werden Lippenpflegestifte sowie desodo rierende Stifte ("Deo-Sticks").Fixed pins according to the invention contain e.g. B. natural or synthetic waxes, Fatty alcohols or fatty acid esters. Lip care sticks and desodo are preferred pens ("deodorant sticks").
Als Treibmittel für erfindungsgemäße, aus Aerosolbehältern versprühbare kosmetische oder dermatologische Zubereitungen sind die üblichen bekannten leichtflüchtigen, ver flüssigten Treibmittel, z. B. Kohlenwasserstoffe (Propan, Butan, Isobutan) geeignet, die allein oder in Mischung miteinander eingesetzt werden können. Auch Druckluft ist vor teilhaft zu verwenden.As a propellant for cosmetic sprayable according to the invention from aerosol containers or dermatological preparations are the usual known volatile, ver liquid blowing agents, e.g. B. hydrocarbons (propane, butane, isobutane) suitable can be used alone or in a mixture with one another. Compressed air is also available to use partially.
Natürlich weiß der Fachmann, daß es an sich nichttoxische Treibgase gibt, die grund sätzlich für die vorliegende Erfindung geeignet wären, auf die aber dennoch wegen be denklicher Wirkung auf die Umwelt oder sonstiger Begleitumstände verzichtet werden sollte, insbesondere Fluorkohlenwasserstoffe und Fluorchlorkohlenwasserstoffe (FCKW).Of course, the expert knows that there are non-toxic propellants per se, the reason would also be suitable for the present invention, but nevertheless due to be environmental impact or other accompanying circumstances should, especially fluorocarbons and chlorofluorocarbons (CFCs).
Bevorzugt können die erfindungsgemäßen Zubereitungen zudem Substanzen enthal ten, die UV-Strahlung im UVB-Bereich absorbieren, wobei die Gesamtmenge der Fil tersubstanzen z. B. 0,1 Gew.-% bis 30 Gew.-%, vorzugsweise 0,5 bis 10 Gew.-%, insbesondere 1 bis 6 Gew.-% beträgt, bezogen auf das Gesamtgewicht der Zubereitung, um kosmetische Zubereitungen zur Verfügung zu stellen, die die Haut vor dem gesamten Bereich der ultravioletten Strahlung schützen. Sie können auch als Sonnenschutzmittel dienen.The preparations according to the invention can preferably also contain substances ten, which absorb UV radiation in the UVB range, the total amount of Fil substances z. B. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, is in particular 1 to 6% by weight, based on the total weight of the Preparation to provide cosmetic preparations that protect the skin protect the entire range of ultraviolet radiation. You can also as Serve sunscreen.
Die UVB-Filter können öllöslich oder wasserlöslich sein. Als öllösliche Substanzen sind z. B. zu nennen: The UVB filters can be oil-soluble or water-soluble. As are oil-soluble substances e.g. B. To name:
- - 3-Benzylidencampher und dessen Derivate, z. B. 3-(4-Methylbenzyliden)campher,- 3-Benzylidene camphor and its derivatives, e.g. B. 3- (4-methylbenzylidene) camphor,
- - 4-Aminobenzoësäure-Derivate, vorzugsweise 4-(Dimethylamino)-benzoësäure(2- ethylhexyl)ester, 4-(Dimethylamino)benzoësäureamylester;- 4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2- ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
- - Ester der Zimtsäure, vorzugsweise 4-Methoxyzimtsäure(2-ethylhexyl)ester, 4- Methoxyzimtsäureisopentylester;Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4- Isopentyl methoxy cinnamate;
- - Ester der Salicylsäure, vorzugsweise Salicylsäure(2-ethylhexyl)ester, Salicylsäu re(4-isopropylbenzyl)ester, Salicylsäurehomomenthylester;- Esters of salicylic acid, preferably salicylic acid (2-ethylhexyl) ester, salicylic acid re (4-isopropylbenzyl) ester, salicylic acid homomethyl ester;
- - Derivate des Benzophenons, vorzugsweise 2-Hydroxy-4-methoxybenzophenon, 2-Hydroxy-4-methoxy-4-methylbenzophenon, 2,2'-Dihydroxy-4-methoxybenzo phenon;Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzo phenone;
- - Ester der Benzalmalonsäure, vorzugsweise 4-Methoxybenzalmalonsäuredi(2- ethylhexyl)ester;Esters of benzalmalonic acid, preferably 4-methoxybenzalmalonic acid di (2- ethylhexyl) ester;
- - 2,4,6-Trianilino-(p-carbo-2'-ethyl-1'-hexyloxy)-1,3,5-triazin- 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine
Als wasserlösliche Substanzen sind vorteilhaft:The following are advantageous as water-soluble substances:
- - 2-Phenylbenzimidazol-5-sulfonsäure und deren Salze, z. B. Natrium-, Kalium- oder Triethanolammonium-Salze,- 2-Phenylbenzimidazole-5-sulfonic acid and its salts, e.g. As sodium, potassium or Triethanolammonium salts,
- - Sulfonsäure-Derivate von Benzophenonen, vorzugsweise 2-Hydroxy-4-methoxy benzophenon-5-sulfonsäure und ihre Salze;- Sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxy benzophenone-5-sulfonic acid and its salts;
- - Sulfonsäure-Derivate des 3-Benzylidencamphers, wie z. B. 4-(2-Oxo-3-bornyli denmethyl)benzolsulfonsäure, 2-Methyl-5-(2-oxo-3-bornylidenmethyl)sulfonsäure und ihre Salze.- Sulfonic acid derivatives of 3-benzylidene camphor, such as. B. 4- (2-Oxo-3-bornyli denmethyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidenemethyl) sulfonic acid and their salts.
Die Liste der genannten UVB-Filter, die erfindungsgemäß Verwendung finden können, soll selbstverständlich nicht limitierend sein.The list of the UVB filters mentioned, which can be used according to the invention, should of course not be limiting.
Es kann auch von Vorteil sein, in Zubereitungen gemäß der Erfindung UVA-Filter ein zusetzen, die üblicherweise in kosmetischen und/oder dermatologischen Zubereitun gen enthalten sind. Bei solchen Substanzen handelt es sich vorzugsweise um Derivate des Dibenzoylmethans, insbesondere um 1-(4'-tert.Butylphenyl)-3-(4'-methoxyphenyl)- propan-1,3-dion und um 1-Phenyl-3-(4'-isopropylphenyl)propan-1-,3-dion. Auch Zube reitungen, die diese Kombinationen enthalten, sind Gegenstand der Erfindung. Es kön nen die gleichen Mengen an UVA-Filtersubstanzen verwendet werden, welche für UVB-Filtersubstanzen genannt wurden. It can also be advantageous to include UVA filters in preparations according to the invention add that usually in cosmetic and / or dermatological preparations gene are included. Such substances are preferably derivatives of dibenzoylmethane, especially 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) - propane-1,3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1-, 3-dione. Also accessories Equations containing these combinations are the subject of the invention. It can the same amounts of UVA filter substances that are used for UVB filter substances were named.
Kosmetische und/oder dermatologische Zubereitungen gemäß der Erfindung können auch anorganische Pigmente enthalten, die üblicherweise in der Kosmetik zum Schut ze der Haut vor UV-Strahlen verwendet werden. Dabei handelt es sich um Oxide des Titans, Zinks, Eisens, Zirkoniums, Siliciums, Mangans, Aluminiums, Cers und Mischun gen davon, sowie Abwandlungen, bei denen die Oxide die aktiven Agentien sind. Be sonders bevorzugt handelt es sich um Pigmente auf der Basis von Titandioxid. Es kön nen die für die vorstehenden Kombinationen genannten Mengen verwendet werden.Cosmetic and / or dermatological preparations according to the invention can also contain inorganic pigments that are commonly used in cosmetics to protect the skin against UV rays. These are oxides of Titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixture and modifications in which the oxides are the active agents. Be pigments based on titanium dioxide are particularly preferred. It can NEN the amounts mentioned for the above combinations are used.
Bei kosmetischen Zubereitungen zur Pflege der Haare handelt es sich beispielsweise um Shampoonierungsmittel, Zubereitungen, die beim Spülen der Haare vor oder nach der Shampoonierung, vor oder nach der Dauerwellbehandlung, vor oder nach der Färbung oder Entfärbung der Haare angewendet werden, um Zubereitungen zum Fönen oder Einlegen der Haare, Zubereitungen zum Färben oder Entfärben, um eine Frisier- und Behandlungslotion, einen Haarlack oder um Dauerwellmittel.Cosmetic preparations for hair care are, for example to shampoo, preparations used when rinsing the hair before or after the shampooing, before or after the permanent wave treatment, before or after the Coloring or discoloration of the hair can be used to prepare preparations Blow-drying or inlaying the hair, preparations for dyeing or decolorizing a Hair styling and treatment lotion, a hair lacquer or permanent waving agent.
Die kosmetischen Zubereitungen enthalten Wirkstoffe und Hilfsstoffe, wie sie übli cherweise für diesen Typ von Zubereitungen zur Haarpflege und Haarbehandlung ver wendet werden.The cosmetic preparations contain active ingredients and auxiliaries as usual This type of preparations for hair care and hair treatment ver be applied.
Als Hilfsstoffe dienen Konservierungsmittel, oberflächenaktive Substanzen, Substanzen zum Verhindern des Schäumens, Emulgatoren, Verdickungsmittel, Fette, Öle, Wachse, organische Lösungsmittel, Bakterizide, Parfüme, Farbstoffe oder Pig mente, deren Aufgabe es ist, die Haare oder die Zubereitung selbst zu färben, Elektro lyte, Zubereitungen gegen das Fetten der Haare.Preservatives, surface-active substances, Anti-foaming agents, emulsifiers, thickeners, fats, Oils, waxes, organic solvents, bactericides, perfumes, dyes or pig elements whose job it is to dye the hair or the preparation itself, electro lyte, preparations for greasing hair.
Kosmetische Zubereitungen, die ein Shampoonierungsmittel oder eine Wasch-, Dusch- oder Badezubereitung darstellen, enthalten vorzugsweise mindestens eine anionische, nicht-ionische oder amphotere oberflächenaktive Substanz oder Gemische daraus, mindestens eine dialkylsubstituierte Carbonsäure im wäßrigen Medium und Hilfsmittel, wie sie üblicherweise dafür verwendet werden.Cosmetic preparations containing a shampoo or a washing, shower or Represent bath preparation, preferably contain at least one anionic, non-ionic or amphoteric surface-active substance or mixtures thereof, at least one dialkyl-substituted carboxylic acid in the aqueous medium and auxiliaries, as they are usually used for this.
Beispiele für oberflächenaktive Substanzen, die erfindungsgemäß vorteilhaft verwen det werden können, sind herkömmliche Seifen, z. B. Fettsäuresalze des Natriums, Al kylsulfate, Alkylethersulfate, Alkan- und Alkylbenzolsulfonate, Sulfoacetate, Sulfobeta ine, Sarcosinate, Amidosulfobetaine, Sulfosuccinate, Sulfobernsteinsäurehalbester, Alkylethercarboxylate, Eiweiß-Fettsäure-Kondensate, Alkylbetaine und Amidobetaine, Fettsäurealkanolamide, Polyglycolether-Derivate.Examples of surface-active substances which are used advantageously according to the invention Det can be conventional soaps, e.g. B. Fatty acid salts of sodium, Al kyl sulfates, alkyl ether sulfates, alkane and alkyl benzene sulfonates, sulfoacetates, sulfobeta ine, sarcosinates, amidosulfobetaines, sulfosuccinates, sulfosuccinic acid semiesters, Alkyl ether carboxylates, protein fatty acid condensates, alkyl betaines and amido betaines, Fatty acid alkanolamides, polyglycol ether derivatives.
Die oberflächenaktive Substanz kann in einer Konzentration zwischen 1 Gew.-% und 50 Gew.-% in dem Shampoonierungsmittel, bzw. der Wasch-, Dusch- oder Badezube reitung, vorliegen.The surface-active substance can be in a concentration between 1% by weight and 50 wt .-% in the shampoo, or the washing, shower or bath accessories horse riding, present.
Liegt die kosmetische oder dermatologische Zubereitung in Form einer Lotion vor, die ausgespült und z. B. vor oder nach der Entfärbung, vor oder nach der Shampoonie rung, zwischen zwei Shampoonierungsschritten, vor oder nach der Dauer wellbehandlung angewendet wird, so handelt es sich dabei z. B. um wäßrige oder wäßrig-alkoholische Lösungen, die gegebenenfalls oberflächenaktive Substanzen enthalten, bevorzugt nicht-ionische oder kationische oberflächenaktive Substanzen, deren Konzentration zwischen 0,1 und 10 Gew.-%, vorzugsweise zwischen 0,2 und 5 Gew.-%, liegen kann. Diese kosmetische oder dermatologische Zubereitung kann auch ein Aerosol mit den üblicherweise dafür verwendeten Hilfsmitteln darstellen.Is the cosmetic or dermatological preparation in the form of a lotion, which rinsed and z. B. before or after decolorization, before or after the shampoo between two shampooing steps, before or after the duration Well treatment is applied, it is z. B. to aqueous or aqueous-alcoholic solutions, optionally surface-active substances contain, preferably non-ionic or cationic surface-active substances, whose concentration is between 0.1 and 10% by weight, preferably between 0.2 and 5 % By weight. This cosmetic or dermatological preparation can also represent an aerosol with the aids commonly used for this.
Eine kosmetische Zubereitung in Form einer Lotion, die nicht ausgespült wird, insbe sondere eine Lotion zum Einlegen der Haare, eine Lotion, die beim Fönen der Haare verwendet wird, eine Frisier- und Behandlungslotion, stellt im allgemeinen eine wäßri ge, alkoholische oder wäßrig-alkoholische Lösung dar und enthält mindestens ein ka tionisches, anionisches, nicht-ionisches oder amphoteres Polymer oder auch Gemische derselben, sowie mindestens eine dialkylsubstituierte Carbonsäure. Die Menge der verwendeten dialkylsubstituierten Carbonsäureester liegt z. B. zwischen 0,1 und 10 Gew.-%, bevorzugt zwischen 0,1 und 3 Gew.-%.A cosmetic preparation in the form of a lotion that is not rinsed off, in particular special a lotion for inlaying the hair, a lotion that is used to blow-dry the hair is used, a hairdressing and treatment lotion, generally represents an aqueous ge, alcoholic or aqueous-alcoholic solution and contains at least one ka ionic, anionic, non-ionic or amphoteric polymer or Mixtures of these, and at least one dialkyl-substituted carboxylic acid. The The amount of dialkyl-substituted carboxylic acid esters used is e.g. B. between 0.1 and 10% by weight, preferably between 0.1 and 3% by weight.
Kosmetische und dermatologische Zubereitungen zur Behandlung und Pflege der Haa re, die mindestens einen erfindungsgemäß verwendeten Ester enthalten, können als Emulsionen vorliegen, die vom nicht-ionischen oder an ionischen Typ sind. Nicht ionische Emulsionen enthalten neben Wasser Öle oder Fettalkohole, die beispiels weise polyethoxyliert oder polypropoxyliert sein können, oder auch Gemische aus den beiden organischen Komponenten. Diese Emulsionen enthalten gegebenenfalls katio nische oberflächenaktive Substanzen. Anionische Emulsionen sind vorzugsweise vom Typ einer Seife und enthalten mindestens eine erfindungsgemäße ethoxylierte oder propoxylierte organische Verbindung mit anionischem oder nicht-ionischem Charakter. Cosmetic and dermatological preparations for the treatment and care of the hair re, which contain at least one ester used according to the invention can as Emulsions are present which are of the non-ionic or ionic type. Not In addition to water, ionic emulsions contain oils or fatty alcohols, for example may be polyethoxylated or polypropoxylated, or mixtures of the two organic components. These emulsions may contain katio niche surface-active substances. Anionic emulsions are preferably from Type of soap and contain at least one ethoxylated or propoxylated organic compound with anionic or non-ionic character.
Kosmetische und dermatologische Zubereitungen zur Behandlung und Pflege der Haa re können als Gele vorliegen, die neben mindestens einem erfindungsgemäß verwen deten Ester und dafür üblicherweise verwendeten Lösungsmitteln noch organische Verdickungsmittel, z. B. Gummiarabikum, Xanthangummi, Natriumalginat, Cellulose- Derivate, vorzugsweise Methylcellulose, Hydroxymethylcellulose, Hydroxyethylcellu lose, Hydroxypropylcellulose, Hydroxypropylmethylcellulose oder anorganische Ver dickungsmittel, z. B. Aluminiumsilikate wie beispielsweise Bentonite, oder ein Gemisch aus Polyethylenglykol und Polyethylenglykolstearat oder -distearat, enthalten. Das Verdickungsmittel ist im Gel z. B. in einer Menge zwischen 0,1 und 30 Gew.-%, bevor zugt zwischen 0,5 und 15 Gew.-%, enthalten.Cosmetic and dermatological preparations for the treatment and care of the hair re can be in the form of gels which are used according to the invention in addition to at least one deten esters and solvents usually used for it still organic Thickeners, e.g. Gum arabic, xanthan gum, sodium alginate, cellulose Derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellu loose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic ver thickener, e.g. B. aluminum silicates such as bentonite, or a mixture made of polyethylene glycol and polyethylene glycol stearate or distearate. The Thickener is in the gel e.g. B. in an amount between 0.1 and 30 wt .-% before contains between 0.5 and 15% by weight.
Vorzugsweise beträgt die Menge der erfindungsgemäß verwendeten Ester in einem für die Haare bestimmten Mittel 0,01 Gew.-% bis 10 Gew.-%, insbesondere 0,5 Gew.-% bis 5 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitungen.The amount of the esters used according to the invention is preferably in one for the hair determined agents 0.01 wt .-% to 10 wt .-%, in particular 0.5 wt .-% to 5 wt .-%, based on the total weight of the preparations.
Die folgenden Beispiele sollen die Verkörperungen der vorliegenden Erfindungen ver deutlichen. Die Angaben beziehen sich stets auf Gewichts-%, sofern nicht andere Angaben gemacht werden. The following examples are intended to illustrate the embodiments of the present invention clear. The data always refer to% by weight, unless other Details are given.
Die durch Zusammenmischung der jeweiligen Bestandteile erhaltene flüssige Phase wird zusammen mit einem Propan-Butan-Gemisch (2 : 7) im Verhältnis 39 : 61 in Aerosol behälter abgefüllt. The liquid phase obtained by mixing the respective components together together with a propane-butane mixture (2: 7) in a ratio of 39: 61 in aerosol filled containers.
Claims (1)
wobei R1, R2, R3 und R4 unabhängig voneinander gewählt werden aus der Gruppe der verzweigten oder unverzweigten Alkylreste mit 1-24 Kohlenstoffatomen und n und m unabhängig voneinander Zahlen von 0 bis 24 darstellen, als antibakterielle, anti mycotische, antiparasitäre oder antivirale Wirkstoffe.Use of esters according to the formula
where R 1 , R 2 , R 3 and R 4 are independently selected from the group of branched or unbranched alkyl radicals having 1-24 carbon atoms and n and m independently of one another are numbers from 0 to 24, as antibacterial, anti mycotic, antiparasitic or antiviral agents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1997142275 DE19742275A1 (en) | 1997-09-25 | 1997-09-25 | Use of branched-chain alkyl alkanoate esters |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1997142275 DE19742275A1 (en) | 1997-09-25 | 1997-09-25 | Use of branched-chain alkyl alkanoate esters |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19742275A1 true DE19742275A1 (en) | 1999-04-01 |
Family
ID=7843557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1997142275 Withdrawn DE19742275A1 (en) | 1997-09-25 | 1997-09-25 | Use of branched-chain alkyl alkanoate esters |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE19742275A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2842706A1 (en) * | 2002-07-26 | 2004-01-30 | Novance | METHOD FOR CONTROLLING THE PROPAGATION OF NON-PERSISTENT VIRUSES, COMPOSITION AND USE |
WO2005027636A3 (en) * | 2003-09-22 | 2005-06-16 | Entomos Res Ltd | Improved topical treatment for the eradication and/or control of ectoparasites |
EP1889640A1 (en) * | 2006-08-18 | 2008-02-20 | Cognis IP Management GmbH | Cosmetic compositions containing ester obtained from 2-butyl-1-octanol |
EP1905419A1 (en) * | 2006-09-20 | 2008-04-02 | Cognis IP Management GmbH | Cosmetic composition and cosmetic oil substances |
EP1858480B1 (en) * | 2005-03-17 | 2013-05-29 | Cognis IP Management GmbH | Cosmetic compositions comprising ester based on 2-propylheptanol |
DE102013009616A1 (en) * | 2013-06-10 | 2014-12-11 | Justus-Liebig-Universität Giessen | Use of esters of saturated short- and medium-chain fatty acids for the prophylaxis and therapy of malassezia-associated diseases and cosmetic problems |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4368188A (en) * | 1981-08-03 | 1983-01-11 | Eli Lilly And Company | Cosmetic toner formulation |
US4368187A (en) * | 1981-08-03 | 1983-01-11 | Eli Lilly And Company | Sensitive-skin care regime |
DE3231705A1 (en) * | 1982-08-26 | 1984-03-01 | Dragoco Gerberding Co Gmbh | Use of branched-chain 2-ethylhexanoic esters as constituent of cosmetic compositions |
DE3231706A1 (en) * | 1982-08-26 | 1984-03-01 | Dragoco Gerberding Co Gmbh | Use of branched-chain isooctanoic esters as constituent of cosmetic compositions |
FR2655265A1 (en) * | 1989-12-01 | 1991-06-07 | Anjou Laboratoire | Emulsifiable three-phase fluid, preparation process, its use in pharmacy or cosmetics and compositions containing it |
EP0651990A1 (en) * | 1993-11-05 | 1995-05-10 | L'oreal | Composition based on C12-C20 esters for make-up removal |
DE4237367C2 (en) * | 1992-11-05 | 1995-10-12 | Beiersdorf Ag | Use of fatty acid esters in cosmetic or dermatological preparations |
DE4434781A1 (en) * | 1994-09-29 | 1996-04-04 | Beiersdorf Ag | Use of fatty acid esters to combat superinfections |
WO1996030000A1 (en) * | 1995-03-30 | 1996-10-03 | Sanofi | Pharmaceutical composition for transdermic delivery |
EP0775478A1 (en) * | 1995-11-23 | 1997-05-28 | Beiersdorf Aktiengesellschaft | Combinations of active ingredients based on partial glycerides and dialkylsubstituted acetic acids efficient against bacteria, mycoses and viruses |
DE19616702A1 (en) * | 1996-03-27 | 1997-10-02 | Hebben & Fischbach Chemietechn | Supply and disposal unit with multi-component resin |
-
1997
- 1997-09-25 DE DE1997142275 patent/DE19742275A1/en not_active Withdrawn
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4368188A (en) * | 1981-08-03 | 1983-01-11 | Eli Lilly And Company | Cosmetic toner formulation |
US4368187A (en) * | 1981-08-03 | 1983-01-11 | Eli Lilly And Company | Sensitive-skin care regime |
DE3231705A1 (en) * | 1982-08-26 | 1984-03-01 | Dragoco Gerberding Co Gmbh | Use of branched-chain 2-ethylhexanoic esters as constituent of cosmetic compositions |
DE3231706A1 (en) * | 1982-08-26 | 1984-03-01 | Dragoco Gerberding Co Gmbh | Use of branched-chain isooctanoic esters as constituent of cosmetic compositions |
FR2655265A1 (en) * | 1989-12-01 | 1991-06-07 | Anjou Laboratoire | Emulsifiable three-phase fluid, preparation process, its use in pharmacy or cosmetics and compositions containing it |
DE4237367C2 (en) * | 1992-11-05 | 1995-10-12 | Beiersdorf Ag | Use of fatty acid esters in cosmetic or dermatological preparations |
EP0651990A1 (en) * | 1993-11-05 | 1995-05-10 | L'oreal | Composition based on C12-C20 esters for make-up removal |
DE4434781A1 (en) * | 1994-09-29 | 1996-04-04 | Beiersdorf Ag | Use of fatty acid esters to combat superinfections |
WO1996030000A1 (en) * | 1995-03-30 | 1996-10-03 | Sanofi | Pharmaceutical composition for transdermic delivery |
EP0775478A1 (en) * | 1995-11-23 | 1997-05-28 | Beiersdorf Aktiengesellschaft | Combinations of active ingredients based on partial glycerides and dialkylsubstituted acetic acids efficient against bacteria, mycoses and viruses |
DE19616702A1 (en) * | 1996-03-27 | 1997-10-02 | Hebben & Fischbach Chemietechn | Supply and disposal unit with multi-component resin |
Non-Patent Citations (3)
Title |
---|
BRUNKE,E.J., KÖSTER,F.-H.: Benetzung und Spreitung als Auswahlkriterien kosmetischer Öle. In: Seifen, Öle, Fette, Wachse, 115.Jg., Nr.2/1980, S.45-47 * |
Chemical Abstracts: Vol.125, Ref. 230196x * |
Vol. 90, Ref. 109797z * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2842706A1 (en) * | 2002-07-26 | 2004-01-30 | Novance | METHOD FOR CONTROLLING THE PROPAGATION OF NON-PERSISTENT VIRUSES, COMPOSITION AND USE |
WO2004010782A3 (en) * | 2002-07-26 | 2004-04-08 | Novance | Method for fighting against non-persistent virus propagation, composition and use |
WO2005027636A3 (en) * | 2003-09-22 | 2005-06-16 | Entomos Res Ltd | Improved topical treatment for the eradication and/or control of ectoparasites |
EP1858480B1 (en) * | 2005-03-17 | 2013-05-29 | Cognis IP Management GmbH | Cosmetic compositions comprising ester based on 2-propylheptanol |
EP1889640A1 (en) * | 2006-08-18 | 2008-02-20 | Cognis IP Management GmbH | Cosmetic compositions containing ester obtained from 2-butyl-1-octanol |
WO2008019794A1 (en) | 2006-08-18 | 2008-02-21 | Cognis Ip Management Gmbh | Cosmetic compositions containing esters of 2-butyloctanol |
EP2051781B1 (en) | 2006-08-18 | 2015-12-02 | Cognis IP Management GmbH | Cosmetic compositions containing ester obtained from 2-butyl-1-octanol |
EP1905419A1 (en) * | 2006-09-20 | 2008-04-02 | Cognis IP Management GmbH | Cosmetic composition and cosmetic oil substances |
DE102013009616A1 (en) * | 2013-06-10 | 2014-12-11 | Justus-Liebig-Universität Giessen | Use of esters of saturated short- and medium-chain fatty acids for the prophylaxis and therapy of malassezia-associated diseases and cosmetic problems |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0742004B1 (en) | Substances effective against bacteria and mycosis | |
EP0876148A1 (en) | Sphingolipids effective against bacteria, parasites, protozoans, fungi and viruses | |
DE19543695A1 (en) | Compositions based on alpha-hydroxyalkanoic acids and squalene, effective against bacteria, Mycota and viruses | |
EP0869797A2 (en) | Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances | |
DE19602111A1 (en) | New active agent combinations useful in cosmetic and dermatological compositions | |
DE19634019A1 (en) | Antimicrobial, antiviral, antiparasitic and antiprotozoal agents | |
EP0775478A1 (en) | Combinations of active ingredients based on partial glycerides and dialkylsubstituted acetic acids efficient against bacteria, mycoses and viruses | |
WO2011038797A1 (en) | Use of magnolol or honokiol as antibacterial, antimycotic, antiparasitic, or antiviral active ingredients | |
WO1997026858A1 (en) | Compounds based on squalene and sphingolipids effective against bacteria, parasites, protozoa, fungi and viruses | |
DE10025124B4 (en) | Combinations of glycerol monoalkyl ethers and aryl-substituted alcohols | |
EP0821948A2 (en) | Combination of active ingredients based on partial glycerides and dialkylsubstituted acetic acids efficient against bacteria, mycoses and viruses | |
EP2793820B1 (en) | Use of an active agent combination of sorbic acid and a hydroxamic acid against dandruff | |
DE19643585A1 (en) | Anti-adhesive formulation containing sphingolipid | |
DE19718777A1 (en) | Use of esters from fatty acids and di- and oligosaccharides against the adhesion of microorganisms | |
DE19634021A1 (en) | Microbial adhesion inhibitor comprising glyco:glycero:lipid | |
DE19516702C2 (en) | Substances effective against bacteria, mycota and viruses | |
DE19826499A1 (en) | Use of lactone, thiolactone and/or dithiolactone derivatives | |
DE19742275A1 (en) | Use of branched-chain alkyl alkanoate esters | |
EP0838155A1 (en) | Anit-adhesive steroids and steroid derivatives | |
DE19643586A1 (en) | Topical sterol formulation for use as deodorant | |
EP2717837B1 (en) | Active ingredient combinations consisting of epsilon-polylysine (epsilon-polylysine) and one or more aromatic esters, aldehydes and/or alcohols | |
EP0771561A2 (en) | Antimycotic compositions, especially active against dandruff, containing aromatic alcohols | |
EP1157686A2 (en) | Combinations of glycerine-monoalkyl ethers and fatty acid glycerides | |
WO1997035570A1 (en) | Use of unsaturated monocarboxylic acids against superinfections | |
EP2793815B1 (en) | Use of dermatological preparation comprising a combination of active ingredients of one or more alkyl ethers of glycerol and one or more physiologically safe hydroxamic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
8139 | Disposal/non-payment of the annual fee |